Omnicell (OMCL) 10-K28 Feb 172016 FY Annual reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - USD ($) $ in Billions	12 Months Ended
Document and Entity Information - USD ($) $ in Billions	Dec. 31, 2016	Feb. 22, 2017	Jun. 30, 2016
Entity [Abstract]
Entity Registrant Name	OMNICELL, Inc
Entity Central Index Key	926,326
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Public Float, non-affiliates			$ 1.2
Entity Common Stock, Shares Outstanding		36,953,613
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 54,488	$ 82,217
Accounts receivable, net of allowances of $4,796 and $1,240, respectively	150,303	107,957
Inventories	69,297	46,594
Prepaid expenses	28,646	19,586
Other current assets	12,674	7,774
Total current assets	315,408	264,128
Property and equipment, net	42,011	32,309
Long-term investment in sales-type leases, net	20,585	14,484
Goodwill	327,724	147,906
Intangible assets, net	190,283	89,665
Long-term deferred tax assets	4,041	2,361
Other long-term assets	35,051	27,894
Total assets	935,103	578,747
Current liabilities:
Accounts payable	27,069	22,646
Accrued compensation	26,722	18,195
Accrued liabilities	31,195	30,133
Long-term debt, current portion, net	8,410	0
Deferred revenue, net	87,516	53,656
Total current liabilities	180,912	124,630
Long-term deferred revenue	17,051	17,975
Long-term deferred tax liabilities	51,592	21,822
Other long-term liabilities	8,210	11,932
Long-term debt, net	245,731	0
Total liabilities	503,496	176,359
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued	0	0
Common stock, $0.001 par value, 100,000 shares authorized; 45,778 and 44,739 shares issued; 36,633 and 35,594 shares outstanding, respectively	46	45
Treasury stock at cost, 9,145 shares outstanding, respectively	(185,074)	(185,074)
Additional paid-in capital	525,758	490,354
Retained earnings	100,396	99,793
Accumulated other comprehensive income	(9,519)	(2,730)
Total stockholders’ equity	431,607	402,388
Total liabilities and stockholders’ equity	$ 935,103	$ 578,747

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Allowances	$ 4,796	$ 1,240
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	45,778,000	44,739,000
Common Stock, Shares, Outstanding	54,923,000	53,884,000
Treasury Stock, Shares Outstanding	9,145,000	9,145,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenues:
Product	$ 517,944	$ 388,397	$ 360,344
Services and other revenues	174,679	96,162	80,556
Total revenues	692,623	484,559	440,900
Cost of revenues:
Cost of product revenues	302,437	198,418	173,419
Cost of services and other revenues	76,386	38,211	33,621
Total cost of revenues	378,823	236,629	207,040
Gross profit	313,800	247,930	233,860
Operating expenses:
Research and development	57,799	35,160	27,802
Selling, general and administrative	249,520	167,581	156,475
Gain on business combination	0	(3,443)	0
Total operating expenses	307,319	199,298	184,277
Income from operations	6,481	48,632	49,583
Interest and other income (expense), net	(8,429)	(2,388)	(1,079)
Income (loss) before provision for income taxes	(1,948)	46,244	48,504
Provision for (benefit from) income taxes	(2,551)	15,484	17,986
Net income	$ 603	$ 30,760	$ 30,518
Net income per share:
Basic (in dollars per share)	$ 0.02	$ 0.86	$ 0.86
Diluted (in dollars per share)	$ 0.02	$ 0.84	$ 0.83
Weighted-average shares:
Basic (in shares)	36,156	35,857	35,650
Diluted (in shares)	36,864	36,718	36,622

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Statement of Comprehensive Income [Abstract]
Net income	$ 603	$ 30,760	$ 30,518
Other comprehensive income (loss), net of reclassification adjustments:
Unrealized gain on interest rate swap contracts	1,245	0	0
Foreign currency translation adjustments	(8,034)	(1,369)	(1,532)
Other comprehensive loss	(6,789)	(1,369)	(1,532)
Comprehensive income (loss)	$ (6,186)	$ 29,391	$ 28,986

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Treasury Stock	Additional Paid-In Capital	Accumulated Earnings (Deficit)	Accumulated Other Comprehensive Income
Common Stock, Beginning of period (in shares) at Dec. 31, 2013		41,842,000
Stockholders' Equity, Beginning of period at Dec. 31, 2013	$ 348,997	$ 41	$ (110,962)	$ 421,232	$ 38,515	$ 171
Treasury Stock, Beginning of period (in shares) at Dec. 31, 2013			(6,837,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	30,518				30,518
Other comprehensive income (loss)	$ (1,532)					(1,532)
Stock repurchases (in shares)	(884,000)		(884,000)
Stock repurchases	$ (24,091)		$ (24,091)
Share-based compensation	12,785			12,785
Issuance of common stock under employee stock plans (in shares)		1,695,000
Issuance of common stock under employee stock plans	21,795	$ 2		21,793
Tax payments related to restricted stock units	(3,744)			(3,744)
Income tax benefits from employee stock plans	5,370			5,370
Common Stock, End of period (in shares) at Dec. 31, 2014		43,537,000
Stockholders' Equity, End of period at Dec. 31, 2014	390,098	$ 43	$ (135,053)	457,436	69,033	(1,361)
Treasury Stock, End of period (in shares) at Dec. 31, 2014			(7,721,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	30,760				30,760
Other comprehensive income (loss)	$ (1,369)					(1,369)
Stock repurchases (in shares)	(1,424,000)		(1,424,000)
Stock repurchases	$ (50,021)		$ (50,021)
Share-based compensation	14,921			14,921
Issuance of common stock under employee stock plans (in shares)		1,202,000
Issuance of common stock under employee stock plans	17,091	$ 2		17,089
Tax payments related to restricted stock units	(3,627)			(3,627)
Income tax benefits from employee stock plans	4,535			4,535
Common Stock, End of period (in shares) at Dec. 31, 2015		44,739,000
Stockholders' Equity, End of period at Dec. 31, 2015	$ 402,388	$ 45	$ (185,074)	490,354	99,793	(2,730)
Treasury Stock, End of period (in shares) at Dec. 31, 2015	(9,145,000)		(9,145,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	$ 603				603
Other comprehensive income (loss)	$ (6,789)					(6,789)
Stock repurchases (in shares)	0
Share-based compensation	$ 19,500			19,500
Issuance of common stock under employee stock plans (in shares)		1,039,000
Issuance of common stock under employee stock plans	17,692	$ 1		17,691
Tax payments related to restricted stock units	(3,490)			(3,490)
Income tax benefits from employee stock plans	1,703			1,703
Common Stock, End of period (in shares) at Dec. 31, 2016		45,778,000
Stockholders' Equity, End of period at Dec. 31, 2016	$ 431,607	$ 46	$ (185,074)	$ 525,758	$ 100,396	$ (9,519)
Treasury Stock, End of period (in shares) at Dec. 31, 2016	(9,145,000)		(9,145,000)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Operating Activities
Net income	$ 603	$ 30,760	$ 30,518
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	58,362	25,639	20,272
Loss on disposal of fixed assets	35	238	167
Impairment of equity investments	0	0	350
Gain on business combinations	0	(3,443)	0
Gain related to contingent liability	(600)	0	0
Share-based compensation expense	19,500	14,921	12,785
Income tax benefits from employee stock plans	1,703	4,535	5,370
Excess tax benefits from employee stock plans	(1,963)	(4,724)	(5,834)
Deferred income taxes	(10,882)	(1,092)	1,402
Amortization of debt financing fees	1,590	0	0
Changes in operating assets and liabilities, net of business acquisitions:
Accounts receivable	8,047	(17,941)	(21,858)
Inventories	(3,362)	(10,032)	1,960
Prepaid expenses	(4,321)	4,049	(4,296)
Other current assets	(1,093)	638	53
Investment in sales-type leases	(9,639)	(4,661)	1,048
Other long-term assets	2,043	496	297
Accounts payable	(4,963)	(2,841)	1,611
Accrued compensation	(2,052)	(2,032)	270
Accrued liabilities	(3,287)	5,456	5,512
Deferred revenue	4,480	(5,521)	13,687
Other long-term liabilities	(6,264)	(683)	1,849
Net cash provided by operating activities	47,937	33,762	65,163
Investing Activities
Purchase of intangible assets, intellectual property and patents	(1,372)	(415)	(327)
Software development for external use	(14,348)	(12,132)	(10,353)
Purchases of property and equipment	(13,445)	(7,542)	(11,922)
Business acquisitions, net of cash acquired	(312,158)	(25,507)	(20,723)
Net cash used in investing activities	(341,323)	(45,596)	(43,325)
Financing Activities
Proceeds from debt, net	287,051	0	0
Repayment of debt and revolving credit facility	(34,500)	0	0
Payment for contingent consideration	(3,000)	0	0
Proceeds from issuances under stock-based compensation plans	17,691	17,091	21,795
Employees' taxes paid related to restricted stock units	(3,490)	(3,627)	(3,744)
Excess tax benefits from employee stock plans	1,963	4,724	5,834
Common stock repurchases	0	(50,021)	(24,091)
Net cash provided by (used in) financing activities	265,715	(31,833)	(206)
Effect of exchange rate changes on cash and cash equivalents	(58)	(4)	(275)
Net increase (decrease) in cash and cash equivalents	(27,729)	(43,671)	21,357
Cash and cash equivalents at beginning of period	82,217	125,888	104,531
Cash and cash equivalents at end of period	54,488	82,217	125,888
Supplemental cash flow information
Cash paid for interest	5,344	76	61
Cash paid for taxes, net of refunds	11,091	11,871	9,161
Supplemental disclosure of non-cash investing activities
Non-cash activity business acquisition	0	7,386	0
Unpaid property and equipment purchases	$ 246	$ 1,398	$ 273

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	12 Months Ended
Organization and Summary of Significant Accounting Policies	Dec. 31, 2016
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	Organization and Summary of Significant Accounting Policies Business Omnicell, Inc. was incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. The Company's major products are automated medication, supply control systems and medication adherence solutions which are sold in its principal market, which is the healthcare industry. The Company's market is primarily located in the United States, Canada and United Kingdom. "Omnicell" or the "Company" refer to Omnicell, Inc. and its subsidiaries. Principles of consolidation The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. GAAP and include all adjustments necessary for the fair presentation of the Company's consolidated financial position, results of operations and cash flows for the periods presented. The Consolidated Financial Statements include the Company's accounts as well as those of its wholly owned subsidiaries after the elimination of intercompany balances and transactions. On January 5, 2016, the Company completed its acquisition of Aesynt Holding Cooperatief U.A. (“Aesynt”). On December 8, 2016, the Company completed its acquisition of Ateb, Inc. and Ateb Canada Ltd. (together, “Ateb”). On April 21, 2015, the Company completed its acquisition of Mach4 Automatisierungstechnik GmbH (“Mach4”). On April 30, 2015, the Company acquired the remaining 85% of the issued and outstanding ordinary shares of Avantec Healthcare Limited (“Avantec”) not already held by Omnicell. The consolidated financial statements include the results of operations of these recently acquired companies, commencing as of their respective acquisition dates. The significant accounting policies of the acquired businesses have been aligned to conform to the accounting policies of Omnicell. Certain prior year amounts have been reclassified to conform to 2016 presentation. These reclassifications include; (i) provision for excess and obsolete inventories and provision for receivables allowance have been reclassified/combined with inventories and accounts receivable within net cash provided by operating activities in the Consolidated Statements of Cash Flows, and (ii) the deferred service revenue and deferred gross profit have been combined under deferred revenue, net. Use of estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company's Consolidated Financial Statements and accompanying Notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. The Company's critical accounting policies are those that affect its financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, accounts receivable and notes receivable from investment in sales-type leases, inventory valuation, capitalized software development costs, valuation and impairment of goodwill, purchased intangibles and long-lived assets, share-based compensation and accounting for income taxes. Segment reporting The Company's Chief Operating Decision Maker ("CODM") is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company's segments using information about its revenues, gross profit, and income from operations. Such evaluation excludes general corporate-level costs that are not specific to either of the reportable segments and are managed separately at the corporate level. Corporate-level costs include expenses related to executive management, finance and accounting, human resources, legal, training and development, and certain administrative expenses. See Note 13, Segment and Geographical Information, for addition information on segment reporting. The operating results of the recently acquired Aesynt, Mach4 and Avantec businesses are included in the Company's Automation and Analytics reportable segment. The operating results of the recently acquired Ateb business is included in the Medication Adherence reportable segment. Foreign currency translation and remeasurement Most of the Company's foreign subsidiaries use the local currency of their respective countries as their functional currency. The Company translates the assets and liabilities of such non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Revenue and expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recorded as foreign currency translation adjustments and included in accumulated other comprehensive income in stockholders’ equity. The Company’s foreign subsidiaries that use the U.S. dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the end of each period, and inventories, property and non-monetary assets and liabilities at historical rates. Gains and losses from such foreign currency remeasurement is recorded in interest and other income (expense). Revenue recognition The Company earns revenues from sales of our medication and medical and surgical supply automation systems along with consumables and related services, which are sold in the healthcare industry, our principal market. Revenues are reported net of discounts and rebates provided to its customers. The Company's customer arrangements typically include one or more of the following deliverables: Products. Software-enabled equipment that manages and regulates the storage and dispensing of pharmaceuticals, consumable blister cards and packaging equipment and other medical supplies. Software. Additional software applications that enable incremental functionality of its equipment. Installation. Installation of equipment as integrated systems at customers' sites. Post-installation technical support. Phone support, on-site service, parts and access to unspecified software upgrades and enhancements, if and when available. Professional services. Other customer services, such as training and consulting. The Company recognizes revenue when the earnings process is complete, based upon its evaluation of whether the following four criteria have been met: Persuasive evidence of an arrangement exists. The Company uses signed customer contracts and signed customer purchase orders as evidence of an arrangement for leases and sales. For service engagements, the Company uses a signed services agreement and a statement of work to evidence an arrangement. Delivery has occurred. Equipment and embedded software product delivery is deemed to occur upon successful installation and receipt of a signed and dated customer confirmation of installation letter, providing evidence that the Company has delivered what a customer ordered. In instances of a customer self-installation, product delivery is deemed to have occurred upon receipt of a signed and dated customer confirmation letter. If a sale does not require installation, the Company recognizes revenue on delivery of products to the customer, including transfer of title and risk of loss, assuming all other revenue criteria are met. For existing distributors, where installation of equipment training has been previously provided and the distributor is certified to install the Company's equipment at the end-user customer facility, the Company recognizes revenue from sales of products to the distributor upon shipment assuming all other revenue criteria are met, net of allowance for rights of return or refund. For new distributors, where the Company has not provided installation of equipment training, revenue on the sales of products to the distributor is deferred until the distributor has completed the Distributor Training Program and has been certified to install the Company's equipment at the end-user facility. For the sale of consumable blister cards, the Company recognizes revenue when title and risk of loss of the products shipped have transferred to the customer, which usually occurs upon shipment from the Company's facilities. Assuming all other revenue criteria are met, the Company recognizes revenue for support services ratably over the related support services contract period. The Company recognizes revenue on training and professional services as they are performed. Fee is fixed or determinable. The Company assesses whether a fee is fixed or determinable at the outset of the arrangement based on the payment terms associated with the transaction. The Company has established a history of collecting under the original contract without providing concessions on payments, products or services. Collection is probable. The Company assesses the probability of collecting from each customer at the outset of the arrangement based on a number of factors, including the customer's payment history and its current creditworthiness. If, in the Company's judgment, collection of a fee is not probable, the Company defers revenue recognition until the uncertainty is removed, which generally means revenue is recognized upon the Company's receipt of cash payment assuming all other revenue criteria are met. The Company's historical experience has been that collection from its customers is generally probable. In arrangements with multiple deliverables, assuming all other revenue criteria are met, the Company recognizes revenue for individual delivered items if they have value to the customer on a standalone basis. The Company allocates arrangement consideration at the inception of the arrangement to all deliverables using the relative selling price method. This method requires the Company to determine the selling price at which each deliverable could be sold if it were sold regularly on a standalone basis. When available, the Company uses vendor-specific objective evidence ("VSOE") of the selling price. VSOE represents the price charged for a deliverable when it is sold separately, or for a deliverable not yet being sold separately, the price established by management with the relevant authority. The Company considers VSOE to exist when approximately 80% or more of its standalone sales of an item are priced within a reasonably narrow pricing range (plus or minus 15% of the median rates). The Company has established VSOE of the selling price for its post-installation technical support services and professional services. When VSOE of selling price is not available, third-party evidence ("TPE") of selling price for similar products and services is acceptable; however, the Company's offerings and market strategy differ from those of its competitors, such that it cannot obtain sufficient comparable information about third parties' prices. If neither VSOE nor TPE are available, the Company uses its best estimates of selling prices ("BESP"). The Company determines BESP considering factors such as market conditions, sales channels, internal costs and product margin objectives and pricing practices. The Company regularly reviews and updates its VSOE and BESP information. The relative selling price method allocates total arrangement consideration proportionally to each deliverable on the basis of its estimated selling price. In addition, the amount recognized for any delivered items cannot exceed that which is not contingent upon delivery of any remaining items in the arrangement. The Company also uses the residual method to allocate revenue between the software products that enable incremental equipment functionality, and thus are not deemed to deliver its essential functionality, and the related post-installation technical support, as these products and services continue to be accounted for under software revenue recognition rules. Under the residual method, the amount allocated to the undelivered elements equals VSOE of fair value of these elements. Any remaining amounts are attributed to the delivered items and are recognized when those items are delivered. A portion of the Company's sales are made through multi-year lease agreements. Under sales-type leases, the Company recognizes revenue for its hardware and software products net of lease execution costs such as post-installation product maintenance and technical support, at the net present value of the lease payment stream once its installation obligations have been met. The Company optimizes cash flows by selling a majority of its non-U.S. government leases to third-party leasing finance companies on a non-recourse basis. The Company has no obligation to the leasing company once the lease has been sold. Some of the Company's sales-type leases, mostly those relating to U.S. government hospitals which comprise approximately 45% of the lease receivable balance, are retained in-house. Interest income in these leases is recognized in product revenue using the effective interest method. Financial Instruments For assets and liabilities measured at fair value, such amounts are based on an expected exit price representing the amount that would be received from the sale of an asset or paid to transfer a liability in a transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs used in valuation techniques are assigned a hierarchical level. The following methods were used to estimate the fair value of each class of financial instruments for which it is practical to estimate that value: Cash and Cash Equivalents and Fair Value of Financial Instruments. The Company classifies investments as cash equivalents if their original or remaining contractual maturity is three months or less at the date of purchase. Cash equivalents are carried at amounts that approximate fair value due to the short period of time to maturity. The Company's cash equivalents are maintained in demand deposit accounts with financial institutions of high credit quality, and are invested in institutional money market funds, short-term bank time deposits and similar short duration instruments with fixed maturities. The Company continuously monitors the credit worthiness of the financial institutions and institutional money market funds in which it invests. The Company has not experienced any credit losses from its cash investments. Foreign currency forward contracts. The Company enters into foreign currency forward contracts to protect its business from the risk that exchange rates may affect the eventual cash flows resulting from intercompany transactions between Omnicell and its foreign subsidiaries. These transactions primarily arise as a result of products manufactured in the United States ("U.S") and sold to foreign subsidiaries in U.S. dollars rather than the subsidiaries' functional currencies. These forward contracts are considered to be financial derivative instruments and are recorded at fair value. Changes in fair values of these financial derivative instruments are either recognized in other comprehensive income or net income depending on whether the derivative has been designated and qualifies as a hedging instrument. Interest rate swap agreements. During the second quarter of 2016, the Company entered into interest rate swap agreements. The interest rate swap agreements, at their inception, qualified for and were designated as cash flow hedging instruments. In accordance with the Derivatives and Hedging Topic of the Accounting Standards Codification ("ASC"), the Company records its interest rate swaps on its consolidated balance sheet at fair value. The effective portion of changes in fair value are recorded in accumulated other comprehensive loss and are subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings. Any ineffective portion is recognized in earnings. Both at inception and on a quarterly basis, the Company performs an effectiveness test. For further information regarding these interest rate swap agreements, please refer to Note 4, "Cash and Cash Equivalents and Fair Value of Financial Instruments". Debt. The Company has entered into a Credit Agreement which provides for (a) a five-year revolving credit facility and (b) a five-year term loan facility (Facilities). The amount borrowed under these facilities is recorded at its carrying value at December 31, 2016. The fair value at December 31, 2016 approximates the carrying value. Accounts receivable and notes receivable from investment in sales-type leases The Company actively manages its accounts receivable to minimize credit risk. The Company typically sells to customers for which there is a history of successful collection. New customers are subject to a credit review process, which evaluates that customer's financial position and ability to pay. The Company continually monitors and evaluates the collectability of its trade receivables based on a combination of factors. The Company records specific allowances for doubtful accounts when it becomes aware of a specific customer's impaired ability to meet its financial obligation to the Company, such as in the case of bankruptcy filings or deterioration of financial position. There were no significant customers that accounted for more than 10% of the Company's accounts receivable as of December 31, 2016 and December 31, 2015 . Uncollectible amounts are charged off against trade receivables and the allowance for doubtful accounts when the Company makes a final determination that there is no reasonable expectation of recovery. Estimates are used in determining the Company's allowances for all other customers based on factors such as current trends, the length of time the receivables are past due and historical collection experience. While the Company believes that its allowance for doubtful accounts receivable is adequate and that the judgment applied is appropriate, such estimated amounts could differ materially from what will actually be uncollectible in the future. The retained in-house leases discussed above are considered financing receivables. The Company's credit policies and its evaluation of credit risk and write-off policies are applied alike to trade receivables and the net investment in sales-type leases. For both, an account is generally past due after thirty days. The financing receivables also have customer-specific reserves for accounts identified for specific impairment and a non-specific reserve applied to the remaining population, based on factors such as current trends, the length of time the receivables are past due and historical collection experience. The retained in-house leases are not stratified by portfolio or class. Sales of accounts receivable The Company records the sale of its accounts receivables as "true sales" in accordance with accounting guidance for transfers and servicing of financial assets. The Company transferred non-recourse accounts receivable totaling $28.7 million , $38.6 million and $62.0 million during fiscal year 2016, 2015, and 2014, respectively, which approximated fair value, to leasing companies on a non-recourse basis. Accounts receivable included approximately $0.2 million , $0.8 million and $1.1 million due from third-party leasing companies for transferred non-recourse accounts receivable as of December 31, 2016 , December 31, 2015 and December 31, 2014 , respectively. Inventory Inventories for 2016 are stated at the lower of cost (utilizing standard costs, applying the first-in, first-out method) or net realizable value, defined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Cost elements included in inventory are direct labor and materials plus applied overhead. The Company routinely assesses on-hand inventory for timely identification and measurement of obsolete, slow-moving or otherwise impaired inventory. The Company writes down its inventory for estimated obsolescence, excess or unmarketable quantities equal to the difference between the cost of the inventory and its estimated market value based on assumptions about future demand and market conditions. If actual future demand or market conditions are less favorable than the Company projected, additional inventory write-downs may be required. The Company has a supply agreement with one primary supplier for construction and supply of several sub-assemblies and inventory management of sub-assemblies used in our hardware products. There are no minimum purchase requirements. The contract with the Company's supplier may be terminated by either the supplier or by the Company without cause and at any time upon delivery of two months' notice. Purchases from this supplier were $47.9 million , $41.7 million and $34.5 million for the years ended December 31, 2016 , December 31, 2015 and December 31, 2014 , respectively. Property and equipment Property and equipment less accumulated depreciation are stated at historical cost. The Company's expenditures for property and equipment primarily are for computer equipment and software used in the administration of its business, and for leasehold improvements to its leased facilities. The Company also develops molds and dies used in long-term manufacturing arrangements with suppliers and for production automation equipment used in the manufacturing of consumable blister card components. Depreciation and amortization of property and equipment are provided over their estimated useful lives, using the straight-line method, as follows: Computer equipment and related software 3 - 5 years Leasehold and building improvements Shorter of the lease term or the estimated useful life Furniture and fixtures 5 - 7 years Equipment 3 - 12 years Depreciation and amortization of property and equipment was $15.0 million , $12.8 million and $11.3 million for the years ended December 31, 2016 , December 31, 2015 and December 31, 2014 , respectively. The Company capitalizes costs related to computer software developed or obtained for internal use in accordance with ASC 350-40, Internal-Use Software . Software obtained for internal use has generally been enterprise-level business and finance software that the Company customizes to meet its specific operational needs. Costs incurred in the application development phase are capitalized and amortized over their useful lives, which is generally five years. Costs recognized in the preliminary project phase and the post-implementation phase are expensed as incurred. The Company capitalized $2.2 million and $1.2 million of costs related to the application development of enterprise-level software that was included in property and equipment during the years ended December 31, 2016 and December 31, 2015 , respectively. Software development costs The Company capitalizes software development costs in accordance with ASC 985-20, Costs of Software to Be Sold, Leased, or Marketed , under which certain software development costs incurred subsequent to the establishment of technological feasibility may be capitalized and amortized over the estimated lives of the related products. The Company establishes feasibility when it completes a working model and amortizes development costs over the estimated lives of the related products ranging from three to five years. The Company capitalized software development costs of $14.3 million and $12.1 million which are included in other assets as of December 31, 2016 and December 31, 2015 , respectively. The Company recorded $7.1 million , $5.8 million and $4.4 million to cost of revenues for amortization of capitalized software development costs for the years ended December 31, 2016 , December 31, 2015 and December 31, 2014 , respectively. All development costs prior to the completion of a working model are recognized as research and development expense. Deferred revenue Deferred revenue arise when customers have been billed and/or have received products and/or services in advance of revenue recognition. The Company's deferred revenue, net, presented as short term consists primarily of (i) unearned revenue on sale of equipment for which installation has not been completed, net of deferred cost of sales for such equipment, and (ii) the current portion of unearned service contracts for which revenue is recognized over their duration. Long-term deferred revenue includes long term portion of unearned service contracts. Business combinations The Company uses the acquisition method of accounting under the authoritative guidance on business combinations. Each acquired company’s operating results are included in the Company's Consolidated Financial Statements starting on the date of acquisition. The purchase price is equivalent to the fair value of consideration transferred. Tangible and identifiable intangible assets acquired and liabilities assumed as of the date of acquisition are recorded at the acquisition date fair value. Goodwill is recognized for the excess of purchase price over the net fair value of assets acquired and liabilities assumed. Amounts allocated to assets and liabilities are based upon fair values. Such valuations require management to make significant estimates and assumptions, especially with respect to the identifiable intangible assets. Management makes estimates of fair value based upon assumptions believed to be reasonable and that of a market participant. These estimates are based on historical experience and information obtained from the management of the acquired companies and the estimates are inherently uncertain. The separately identifiable intangible assets generally include customer relationships, technology, and trade names. Goodwill and intangible assets Goodwill. The Company reviews goodwill for impairment on an annual basis on the first day of the fourth quarter of each year at the reporting unit level. The Company's reporting units are the same as its operating segments, which are Automation and Analytics and Medication Adherence. A qualitative assessment is initially made to determine whether it is necessary to perform quantitative testing. This initial assessment includes, among others, consideration of: (i) past, current and projected future earnings and equity; (ii) recent trends and market conditions; and (iii) valuation metrics involving similar companies that are publicly-traded and acquisitions of similar companies, if available. If this initial qualitative assessment indicates that it is more likely than not that impairment exists, or if the Company decides to bypass this option, it proceeds to a two-step impairment test. The first step ("Step 1") involves a comparison between the estimated fair values of the Company's reporting units with their respective carrying amounts including goodwill. The methods for estimating reporting unit values include asset and liability fair values and other valuation techniques, such as discounted cash flows and multiples of earnings or revenues. If the carrying value exceeds estimated fair value, there is an indication of potential impairment, and the second step is performed to measure the amount of impairment. The second step involves calculating an implied fair value of goodwill by measuring the excess of the estimated fair value of the reporting units over the aggregate estimated fair values of the individual assets less liabilities. If the carrying value of goodwill exceeds the implied fair value of goodwill, an impairment charge is recorded for the excess. To determine each reporting unit's fair value in the second step, the Company uses the income approach which is based on the estimated discounted future cash flows of that reporting unit. The estimated fair value of each reporting unit under the income approach is corroborated with the market approach, which measures the value of a business through an analysis of recent sales or offerings of a comparable entity. The Company also considers its market capitalization on the date of the analysis to ensure the reasonableness of the sum of its reporting units’ estimated fair value. The Company performed a Step 1 impairment analysis as of October 1, 2016 for its Medication Adherence reporting unit. The Company determined that the fair value of this reporting unit exceeded the carrying value by more than 25%, and thus no impairment was indicated. Additionally, the Company performed a Step 0 impairment assessment analysis as of October 1, 2016 for its Automation and Analytics reporting unit taking into consideration past, current and projected future earnings, recent trends and market conditions; and valuation metrics involving similar companies that are publicly-traded. Based on the result of this analysis it is more likely than not an impairment does not e xist. Intangible assets. In connection with the Company's acquisitions, it generally recognizes assets for customer relationships, technology and trade names. Intangible assets are carried at cost less accumulated amortization. Such amortization is provided on a straight-line basis or on an accelerated basis based on a pattern of economic benefit that is expected to be obtained over the estimated useful lives of the respective assets, generally from 1 to 30 years. Amortization for developed technology and backlog is recognized in cost of product revenues, and amortization for customer relationships, non-compete agreements, and trade names is recognized in selling, general and administrative expenses. The Company assesses the impairment of identifiable intangible assets whenever events or changes in circumstances indicate that an asset's carrying amount may not be recoverable. Recoverability of an asset is measured by the comparison of the carrying amount to the sum of the undiscounted estimated future cash flows the asset is expected to generate, offset by estimated future costs to dispose of the product to which the asset relates. If an asset is considered to be impaired, the amount of such impairment would be measured as the difference between the carrying amount of the asset and its fair value. The Company's cash flow assumptions are based on historical and forecasted future revenue, operating costs, and other relevant factors. Assumptions and estimates about the remaining useful lives of the Company's intangible assets are subjective and are affected by changes to its business strategies. If management’s estimates of future operating results change, or if there are changes to other assumptions, the estimate of the fair value of the Company's assets could change significantly. Such change could result in impairment charges in future periods, which could have a significant impact on the Company's operating results and financial condition. Valuation of share-based awards The Company accounts for share-based compensation in accordance with ASC 718, Stock Compensation ("ASC 718"). The Company recognizes compensation expense related to stock-based compensation based on the grant date estimated fair value. The Company amortizes the fair value of the employee stock awards on a straight-line basis over the requisite service period of the award, which is generally the vesting period. The Company estimates the fair value of stock-based compensation awards using the Black-Scholes option pricing model, which requires the following inputs: expected life, expected volatility, risk-free interest rate, expected dividend yield rate, exercise price, and closing price of its common stock on the date of grant. The expected volatility is based on a combination of historical and market-based implied volatility, and the expected life of the awards is based on the Company's historical experience of employee stock option exercises, including forfeitures. The valuation assumptions used in estimating the fair value of employee share-based awards may change in future periods. The Company calculates its pool of excess tax benefits available within additional paid-in capital in accordance with the provisions of ASC 718. Accounting for income taxes The Company records an income tax provision (benefit) for the anticipated tax consequences of the reported results of operations. In accordance with U.S. GAAP, the provisi

Business Combinations

Business Combinations	12 Months Ended
Business Combinations	Dec. 31, 2016
Business Combinations [Abstract]
Business Combinations	Business Combinations 2016 Acquisition Activity On January 5, 2016, the Company completed the acquisition of all of the membership interests of Aesynt pursuant to the Aesynt Securities Purchase Agreement. Aesynt is a provider of automated medication management systems, including dispensing robots with storage solutions, medication storage and dispensing carts and cabinets, I.V. sterile preparation robotics and software, including software related to medication management. The total consideration was $271.5 million , net of cash acquired of $8.2 million . The results of Aesynt's operations have been included in our consolidated results of operations as of the time of the acquisition, and presented as part of the Automation & Analytics segment. On December 8, 2016, the Company completed its acquisition of ateb, Inc., and Ateb Canada Ltd. (together, “Ateb”) pursuant to Ateb's Securities Purchase Agreement for $40.7 million of cash consideration, net of $0.9 million cash acquired. The cash consideration, included the repayment of Ateb indebtedness and other adjustments provided for in the Ateb's Securities Purchase Agreement. Ateb is a provider of pharmacy-based patient care solutions and the medication synchronization solutions leader to independent and chain pharmacies. The results of Ateb's operations have been included in our consolidated results of operations as of the time of the acquisition, and presented as part of the Medication Adherence segment. The Company accounted for the acquisitions of Aesynt and Ateb in accordance with the authoritative guidance on business combinations; therefore, the tangible and intangible assets acquired and liabilities assumed were recorded at fair value on the acquisition dates, respectively. The following table represents the allocation of the purchase price to the assets acquired and the liabilities assumed by the Company during each acquisition, respectively, reconciled to the purchase price transferred included in the Company's Consolidated Balance Sheet: Aesynt Ateb (preliminary) Total (In thousands) Cash $ 8,164 $ 902 $ 9,066 Accounts receivable 43,312 7,905 51,217 Inventory 19,021 225 19,246 Other current assets 3,787 1,239 5,026 Total current assets 74,284 10,271 84,555 Property and equipment 10,389 2,447 12,836 Intangible assets 123,700 12,500 136,200 Goodwill 163,599 20,832 184,431 Other non-current assets 968 1,009 1,977 Total assets 372,940 47,059 419,999 Current liabilities 26,753 2,314 29,067 Deferred revenue, net 25,512 2,776 28,288 Non-current deferred tax liabilities 38,622 — 38,622 Other non-current liabilities 2,431 367 2,798 Total liabilities 93,318 5,457 98,775 Total purchase price 279,622 41,602 321,224 Total purchase price, net of cash received $ 271,458 $ 40,700 $ 312,158 The $163.6 million of goodwill arising from the Aesynt acquisition is primarily attributed to sales of future products and services and Aesynt's assembled workforce. The Aesynt acquisition created one of the broadest product portfolio in the industry with significant offerings in automated dispensing systems, central pharmacy robotics, I.V. robotics and enterprise analytics. The goodwill has been assigned to the Automation & Analytics segment and is not deductible for tax purposes. Since the acquisition, the Company adjusted the preliminary value assigned to goodwill by $1.2 million to reflect measurement period adjustments related to account receivable, inventory, and other assets and liabilities (inclusive of deferred taxes) of $1.6 million , $1.1 million and ($3.9) million respectively. The $20.8 million of goodwill arising from the Ateb acquisition is primarily attributed to sales of future products and services and Ateb's assembled workforce. The Ateb acquisition positions further the Company’s medication adherence portfolio, helping to expand the retail pharmacy footprint. Intangibles eligible for recognition separate from goodwill were those that satisfied either the contractual/legal criterion or the separability criterion in the accounting guidance. The identifiable intangible assets acquired and their estimated useful lives for amortization are as follows: Aesynt Ateb (preliminary) Fair value Weighted Fair value Weighted (In thousands) (In years) (In thousands) (In years) Customer relationships $ 58,200 14-16 $ 8,900 12 Developed technology 38,800 8 3,400 5 Backlog 20,200 1-3 — - In-process research and development ("IPR&D") (1) 3,900 - — - Non-compete 1,800 3 100 1 Trade names 800 1 100 1 Total purchased intangible assets $ 123,700 $ 12,500 (1) The amortization of the in-process R&D assets begins when the in-process R&D projects are complete. Aesynt Acquisition Customer relationships represent the fair value of the underlying relationships and agreements with Aesynt’s customers, acquired developed technology represents the fair value of Aesynt products that have reached technological feasibility and were part of Aesynt’s product offerings at the date of acquisition, backlog represents the fair value of sales order backlog at the date of acquisition, non-compete intangible asset represents the fair value of non-compete agreements with former key members of Aesynt's management, and trade name represents the fair value of brand and name recognition associated with the marketing of Aesynt’s products and services. In-process research and development ("IPR&D") represents the fair value of incomplete Aesynt research and development projects that had not reached technological feasibility as of the date of acquisition. Incremental costs incurred for those projects are expensed as incurred in research and development. The fair value of Aesynt trade names, acquired developed technology, and acquired IPR&D was determined based on an income approach using the relief-from-royalty method at the royalty rates of 0.5% , 4% to 8% and 12.5% , respectively. The fair value of customer relationships, backlog, and non-compete intangible assets were determined based on an income approach using the discounted cash flow method, at the discounted rates of 13% , 10% and 13% , respectively. The intangible assets, except customer relationship and IPR&D, are being amortized over their estimated useful lives using the straight line method of amortization. The customer relationship intangible asset is being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained. In accordance with authoritative guidance, the IPR&D is accounted for as an indefinite-lived intangible asset until completion or abandonment of the associated research and development efforts. IPR&D is tested for impairment during the period it is considered an indefinite lived asset. IPR&D related projects are expected to be completed in two to three years. As of December 31, 2016 , none of the IPR&D projects have been completed, and they have progressed as previously estimated. Ateb Acquisition Customer relationships represent the fair value of the underlying relationships and agreements with Ateb’s customers expected to result in future sales, acquired developed technology represents the fair value of Ateb intellectual property incorporated in their products, non-compete intangible asset represents the fair value of non-compete agreements with former key members of Ateb's management, and trade name represents the fair value of brand and name recognition associated with the marketing of Ateb’s products and services. The fair value of Ateb trade names and acquired developed technology was determined based on an income approach using the relief-from-royalty method at the royalty rates of 0.5% and 5% to 6% , respectively. The fair value of customer relationships, and non-compete intangible assets were determined based on an income approach using the discounted cash flow method, both using a 15% discount rate. The intangible assets for non-compete agreements and trade name are being amortized over their estimated useful lives using the straight line method of amortization. The intangible assets for customer relationship and developed technology are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained. The Company incurred approximately $9.3 million in acquisition-related costs related to the Aesynt acquisition of which $6.4 million and $2.9 million were recognized in the years ended December 31, 2016 and 2015 , respectively. These costs are included in selling, general and administrative expenses in the Company's Consolidated Statement of Operations. During the year ended December 31, 2016 , the Company incurred and expensed approximately $1.7 million of acquisition-related costs for Ateb. Revenues and losses from the Aesynt operations since the acquisition date through December 31, 2016 were $155.8 million and $40.5 million , respectively. Losses from operations includes the amortization of intangible assets of $27.3 million for the period presented. Revenues and losses from the Ateb operations since the acquisition date through December 31, 2016 were $1.7 million and $0.1 million , respectively, which included $0.3 million of amortization expense of intangible assets. 2015 Acquisition Activity Mach4 Acquisition On April 21, 2015 , the Company completed its acquisition of Mach4, a privately held German limited liability company with its registered office in Bochum, Germany pursuant to a share purchase agreement (the “Mach4 Agreement”), under which Omnicell International, Inc., a wholly-owned subsidiary of Omnicell Inc., purchased the entire issued share capital of Mach4 (the “Mach4 Acquisition”). Mach4 manufactures robotic dispensing systems used by retail and hospital pharmacies and the Mach4 acquisition provides the Company with a more robust product offering that is intended to be leveraged to create opportunities to sell additional Omnicell medication cabinets. The robotic storage and dispensing product offering provides the Company with a solution to better compete for international market share. Pursuant to the terms of the Mach4 Agreement, the Company paid approximately $17.3 million in cash after adjustments provided for in the Mach4 Agreement, of which $2.7 million was placed in an escrow fund, which were distributed to Mach4's former stockholders. Avantec Acquisition On April 30, 2015 , the Company completed the acquisition of Avantec, the privately-held distributor of the Company’s products in the United Kingdom, pursuant to a share purchase agreement (the “Avantec Agreement”). Pursuant to the Avantec Agreement, the Company acquired the remaining 85% of issued and outstanding ordinary shares of Avantec that was not previously owned by the Company. Avantec develops medication and supply automation products that complement the Company's solutions for configurations suited to the United Kingdom marketplace, and had been the exclusive distributor of the Company's medication and supply automation solutions since 2005 in the United Kingdom. Pursuant to the terms of the Avantec Agreement, the Company agreed to pay $12.0 million in cash (the “Purchase Consideration”) and potential earn-out payments of up to $3.0 million payable after December 31, 2015 and an additional $3.0 million payable after December 31, 2016 , based on bookings targets. The fair value of these potential earn-out payments as of the acquisition date was $5.6 million . Pursuant to the terms of the Avantec Agreement, the Company retained $1.8 million of the Purchase Consideration to be held to settle any future indemnification claims within 18 months period that the Company may make following the closing. During the year 2016, the Company paid out $3.0 million in earn-out payments, $1.8 million in held back payments for future indemnifications, and recognized $0.6 million of contingent gain as certain booking targets were not met. The Company expects to pay the remaining earn-out amount of $2.4 million in 2017. The fair value of the contingent consideration liability related to Avantec is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this obligation are recorded as income or expense within other expense in the Company's Consolidated Statements of Operations. The significant unobservable inputs used in the fair value measurement of the contingent consideration are the achievement of booking targets and the discount rate. Significant increases or decreases in any of those inputs in isolation would result in a significantly lower or higher fair value measurement. Prior to the Avantec Acquisition, the Company accounted for its 15% ownership interest in Avantec as an equity-method investment. The Avantec acquisition date carrying book value of the Company's previous equity interest was $1.3 million . This transaction was accounted for as a step acquisition, which required the Company to re-measure its previously held 15% ownership interest to fair value and record the difference between the fair value and carrying value as a gain. The fair value of the equity investment was determined to be $4.7 million which resulted in a gain of $3.4 million . The Company accounted for the acquisitions of March4 and Avantec in accordance with the authoritative guidance on business combinations; therefore, the tangible and intangible assets acquired and liabilities assumed were recorded at fair value on the acquisition dates, respectively. The following table represents the allocation of the purchase price to the assets acquired and the liabilities assumed by the Company during each acquisition, respectively, reconciled to the purchase price transferred included in the Company's Consolidated Balance Sheet. Mach4 Avantec Total (In thousands) Cash $ 397 $ 3,392 $ 3,789 Accounts receivable 3,743 3,607 7,350 Inventory 3,580 1,428 5,008 Deferred tax assets and other current assets 368 89 457 Total current assets 8,088 8,516 16,604 Property and equipment 463 — 463 Intangibles 7,710 6,341 14,051 Goodwill 10,591 15,606 26,197 Other non-current assets 52 — 52 Total assets 26,904 30,463 57,367 Current liabilities 3,684 4,125 7,809 Non-current deferred tax liabilities 2,564 1,269 3,833 Deferred service revenue and gross profit 2,314 928 3,242 Other non-current liabilities 1,056 — 1,056 Total liabilities 9,618 6,322 15,940 Total purchase price 17,286 24,141 41,427 Total purchase price, net of cash received $ 16,889 $ 20,749 $ 37,638 The goodwill arising from these acquisitions is primarily attributed to sales of future products and services and the assembled workforce. Goodwill is not deductible for tax purposes. Goodwill is not being amortized but is reviewed annually for impairment or more frequently if impairment indicators arise, in accordance with authoritative guidance. Intangible assets acquired and their respective estimated remaining useful lives over which each asset will be amortized are as follows: Mach4 Avantec Fair value Weighted Fair value Weighted (In thousands) (In years) (In thousands) (In years) Developed technology $ 3,290 8 $ — — Trade name 850 6 92 2 Customer relationships 3,570 10 5,834 12 Backlog — — 415 2 Total purchased intangible assets $ 7,710 $ 6,341 Pro forma financial information The following table presents certain unaudited pro forma information for illustrative purposes only, for the years ended December 31, 2016 and 2015 as if these acquisitions had been acquired on January 1, 2015. The pro forma information is not indicative of what would have occurred had the acquisitions taken place on January 1, 2015. The unaudited pro forma information combines the historical results of the acquisitions with the Company's consolidated historical results and includes certain adjustments reflecting the estimated impact of fair value adjustments for the respective periods. The pro forma adjustments include the impact of fair value adjustment related to deferred revenue, inventory fair value adjustment, amortization of intangible assets, stock-based compensation expense, interest expense and amortization of deferred issuance cost, and certain classification to conform to Omnicell's accounting policies. Twelve months ended December 31, 2016 2015 (In thousands, except per share data) Pro forma net revenues $ 718,439 $ 522,317 Pro forma net income (loss) $ (1,330 ) $ 1,978 Pro forma net income (loss) per share $ (0.04 ) $ 0.05 Weighted average number of shares 36,156 36,699

Net Income Per Share

Net Income Per Share	12 Months Ended
Net Income Per Share	Dec. 31, 2016
Earnings Per Share [Abstract]
Net Income Per Share	Net Income Per Share Basic net income per share is computed by dividing net income for the period by the weighted-average number of shares outstanding during the period. Diluted net income per share is computed by dividing net income for the period by the weighted-average number of shares, less shares repurchased, plus, if dilutive, potential common stock outstanding during the period. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards and restricted stock units computed using the treasury stock method. The anti-dilutive weighted-average dilutive shares related to stock award plans are excluded from the computation of the diluted net income per share. The calculation of basic and diluted net income per share is as follows: Year Ended December 31, December 31, December 31, (In thousands, except per share data) Net income $ 603 $ 30,760 $ 30,518 Weighted-average shares outstanding — basic 36,156 35,857 35,650 Add: Dilutive effect of employee stock plans 708 861 972 Weighted-average shares outstanding — diluted 36,864 36,718 36,622 Net income per share — basic $ 0.02 $ 0.86 $ 0.86 Net income per share — diluted $ 0.02 $ 0.84 $ 0.83 Anti-dilutive weighted-average shares related to stock award plans 1,345 555 640

Cash and Cash Equivalents and F

Cash and Cash Equivalents and Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Cash and Cash Equivalents and Fair Value of Financial Instruments	Cash and Cash Equivalents and Fair Value of Financial Instruments Cash and cash equivalents include money market funds, which have original maturities of three months or less. Due to the short duration to maturity, the carrying value of such financial instruments approximates the estimated fair value. Cash and cash equivalents at December 31, 2016 and December 31, 2015 were as follows: December 31, 2016 December 31, 2015 (In thousands) Cash $ 54,488 $ 72,103 Cash equivalents — 10,114 Total cash and cash equivalents $ 54,488 $ 82,217 Fair value hierarchy The Company measures its financial instruments at fair value. The Company’s cash equivalents are classified within Level 1 of the fair value hierarchy as they are valued primarily using quoted market prices utilizing market observable inputs. The Company's interest rate swap contracts and foreign currency contracts are classified within Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments. The Company's contingent consideration liability related to the Avantec acquisition is classified as Level 3 as valuation inputs are unobservable in the market and significant to the instrument’s valuation. During the year ended December 31, 2016, the Company paid $3.0 million for contingent consideration and recorded $0.2 million for accrued interest. Additionally, the Company determined the final payout amount for the remaining contingent consideration and reduced the liability from $3.0 million to $2.4 million . The reduction of the contingent liability resulted in a gain of $0.6 million which is disclosed within "Interest and other income (expense), net" capture of the Statement of Operations for the year ended December 31, 2016. The following table represents the fair value hierarchy of the Company’s financial assets measured at fair value as of December 31, 2016 : Level 1 Level 2 Level 3 Total (In thousands) Interest rate swap contracts $ — $ 1,245 $ — $ 1,245 Total financial assets $ — $ 1,245 $ — $ 1,245 Contingent consideration liability $ — $ — $ 2,400 $ 2,400 Total financial liabilities $ — $ — $ 2,400 $ 2,400 The significant unobservable inputs used in the fair value measurement of the contingent consideration classified as level 3 above are the achievement of booking targets and the discount rate. There have been no transfers between fair value measurement levels during the year ended December 31, 2016 and December 31, 2015 . The following table represents the fair value hierarchy of the Company’s financial assets measured at fair value as of December 31, 2015 : Level 1 Level 2 Level 3 Total (In thousands) Money market funds $ 10,114 $ — $ — $ 10,114 Forward contracts — 32 — 32 Total financial assets $ 10,114 $ 32 $ — $ 10,146 Contingent consideration liability $ — $ — $ 5,823 $ 5,823 Total financial Liabilities $ — $ — $ 5,823 $ 5,823 Foreign Currency Risk Management The Company operates in foreign countries, which expose it to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, the most significant of which is the British Pound and Euro. In order to manage foreign currency risk, at times the Company enters into foreign exchange forward contracts to mitigate risks associated with changes in spot exchange rates of mainly non-functional currency denominated assets or liabilities of our foreign subsidiaries. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. By working only with major banks and closely monitoring current market conditions, the Company seeks to limit the risk that counterparties to these contracts may be unable to perform. The foreign exchange forward contracts are measured at fair value and reported as other current assets or accrued liabilities on the Consolidated Balance Sheets. The derivative instruments the Company uses to hedge this exposure are not designated as hedges. Any gains or losses on the foreign exchange forward contracts are recognized in earnings as Other Income/Expense in the period incurred in the Consolidated Statements of Operations. The Company does not enter into derivative contracts for trading purposes. At December 31, 2016, the Company had no outstanding foreign exchange forward contracts. The aggregate notional value of these outstanding foreign exchange contracts as of December 31, 2015 was $0.4 million . Interest Rate Swap Contracts The Company uses interest rate swap agreements to protect the Company against adverse fluctuations in interest rates by reducing its exposure to variability in cash flows relating to interest payments on a portion of its outstanding debt. The Company's interest rate swaps, which are designated as cash flow hedges, involve the receipt of variable amounts from counterparties in exchange for the Company making fixed-rate payments over the life of the agreements. The Company does not hold or issue any derivative financial instruments for speculative trading purposes. During 2016, the Company entered into an interest rate swap agreement with a combined notional amount of $100.0 million with one counter-party that is effective beginning on June 30, 2016 and maturing on April 30, 2019. The swap agreement requires the Company to pay a fixed rate of 0.8% and provides that the Company will receive a variable rate based on the one month LIBOR rate subject to LIBOR floor of 0.0% . Amounts payable by or due to the Company will be net settled with the respective counter-party on the last business day of each month, commencing July 31, 2016. The fair value of the interest rate swap agreements at December 31, 2016 was $1.2 million . There were no amounts reclassified into current earnings due to ineffectiveness during the periods presented.

Balance Sheet Components

Balance Sheet Components	12 Months Ended
Balance Sheet Components	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Components	Balance Sheet Components Balance sheet details as of December 31, 2016 and December 31, 2015 are presented in the tables below: December 31, December 31, (In thousands) Inventories: Raw materials $ 14,322 $ 11,582 Work in process 7,800 1,653 Finished goods 47,175 33,359 Total inventories $ 69,297 $ 46,594 Prepaid expenses Prepaid commissions $ 13,176 $ 9,240 Other prepaid expenses 15,470 10,346 Total prepaid expense $ 28,646 $ 19,586 Property and equipment: Equipment $ 64,384 $ 43,533 Furniture and fixtures 6,517 5,897 Leasehold improvements 9,778 9,063 Software 35,607 30,693 Construction in progress 7,211 3,651 Property and equipment, gross 123,497 92,837 Accumulated depreciation and amortization (81,486 ) (60,528 ) Total property and equipment, net $ 42,011 $ 32,309 Other long term assets: Capitalized software, net $ 33,233 $ 26,011 Other assets 1,818 1,883 Total other long term assets, net $ 35,051 $ 27,894 Accrued liabilities: Advance payments from customers $ 7,030 $ 8,327 Rebates and lease buyouts 4,025 4,702 Group purchasing organization fees 3,737 2,983 Taxes payable 4,003 2,768 Other accrued liabilities 12,400 11,353 Total accrued liabilities $ 31,195 $ 30,133 The following table summarizes the changes in accumulated balances of other comprehensive income (loss) for the years ended December 31, 2016 and 2015 : Foreign currency translation adjustments Unrealized gain (loss) on interest rate swap hedges Total (In thousands) Balance as of December 31, 2014 $ (1,361 ) $ — $ (1,361 ) Other comprehensive income (loss) before reclassifications (1,369 ) — (1,369 ) Amounts reclassified from other comprehensive income (loss), net of tax — — — Net current-period other comprehensive income (loss), net of tax (1,369 ) — (1,369 ) Balance as of December 31, 2015 (2,730 ) — (2,730 ) Other comprehensive income (loss) before reclassifications (8,034 ) 1,385 (6,649 ) Amounts reclassified from other comprehensive income (loss), net of tax — (140 ) (140 ) Net current-period other comprehensive income (loss), net of tax (8,034 ) 1,245 (6,789 ) Balance as of December 31, 2016 $ (10,764 ) $ 1,245 $ (9,519 )

Net Investment in Sales-Type Le

Net Investment in Sales-Type Leases	12 Months Ended
Net Investment in Sales-Type Leases	Dec. 31, 2016
Leases [Abstract]
Net Investment in Sales-Type Leases	Net Investment in Sales-Type Leases On recurring basis, the Company enters into sales-type lease transactions which vary in length from 1.0 year to 5.0 years . The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at December 31, 2016 and December 31, 2015 : December 31, December 31, (In thousands) Net minimum lease payments to be received $ 33,591 $ 22,255 Less: unearned interest income portion (2,763 ) (1,014 ) Net investment in sales-type leases 30,828 21,241 Less: short-term portion (1) (10,243 ) (6,757 ) Long-term net investment in sales-type leases $ 20,585 $ 14,484 (1) The short-term portion of the net investments in sales-type leases is included in the other current assets on the Consolidated Balance Sheets. The Company evaluates its sales-type leases individually and collectively for impairment. The allowance for credit losses were $0.3 million and $0.2 million as of December 31, 2016 and December 31, 2015 respectively. At December 31, 2016 , the future minimum lease payments to be received under sales-type leases are as follows: Year ended December 31, (In thousands) 2017 $ 11,172 2018 7,934 2019 6,240 2020 4,303 2021 2,396 Thereafter 1,546 Total $ 33,591

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
Goodwill and Intangible Assets	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill The changes in the carrying amount of goodwill are as follows: Automation and Analytics Medication Adherence Total (In thousands) Net balance as of December 31, 2014 $ 28,543 $ 94,177 $ 122,720 Additions (1) 26,197 — 26,197 Adjustments (2) (424 ) (587 ) (1,011 ) Net balance as of December 31, 2015 54,316 93,590 147,906 Additions (3) 163,599 20,832 184,431 Adjustments (2) (2,833 ) (1,780 ) (4,613 ) Net balance as of December 31, 2016 $ 215,082 $ 112,642 $ 327,724 _________________________________________________ (1) Additions to goodwill as a result of the Mach4 and Avantec acquisitions in April 2015, including a $0.1 million adjustment to the purchase price in the fourth quarter of 2015 for Mach4. (2) Adjustments reflect foreign currency exchange rate fluctuations. (3) Additions to goodwill as a result of the Aesynt acquisition in January 2016 and Ateb acquisition in December 2016. Intangible assets, net The carrying amounts of intangibles as of December 31, 2016 were as follows: December 31, 2016 Gross carrying amount Accumulated amortization Foreign currency exchange rate fluctuations Net carrying amount Useful life (years) (In thousands, except for years) Customer relationships $ 133,358 $ (20,930 ) $ (596 ) $ 111,832 1 - 30 Acquired technology 73,599 (13,287 ) (159 ) 60,153 3 - 20 Backlog 20,550 (14,083 ) — 6,467 1 - 3 Trade names 8,667 (3,887 ) (31 ) 4,749 1 - 12 Patents 3,154 (1,264 ) — 1,890 2 - 20 Non-compete agreements 1,900 (608 ) — 1,292 3 In process technology 3,900 — — 3,900 - Total intangibles assets, net $ 245,128 $ (54,059 ) $ (786 ) $ 190,283 The carrying amounts of intangibles as of December 31, 2015 were as follows: December 31, 2015 Gross carrying amount Accumulated amortization Foreign currency exchange rate fluctuations Net carrying amount Useful life (years) (In thousands, except for years) Customer relationships $ 69,554 $ (11,315 ) $ (719 ) $ 57,520 5 - 30 Acquired technology 30,870 (6,088 ) 59 24,841 3 - 20 Backlog 415 (163 ) (11 ) 241 2 Trade names 8,052 (2,551 ) (14 ) 5,487 1 - 12 Patents 1,960 (384 ) — 1,576 2 - 20 Total intangibles assets, net $ 110,851 $ (20,501 ) $ (685 ) $ 89,665 Amortization expense of intangible assets was $36.1 million , $6.9 million and $4.6 million for the years ended December 31, 2016 , December 31, 2015 and December 31, 2014 , respectively. The estimated future amortization expenses for intangible assets are as follows: For the year ended December 31, (In thousands) 2017 $ 25,173 2018 22,840 2019 17,402 2020 16,255 2021 14,854 Thereafter (including IPR&D) 93,759 Total $ 190,283

Debt and Credit Agreement

Debt and Credit Agreement	12 Months Ended
Debt and Credit Agreement	Dec. 31, 2016
Debt Disclosure [Abstract]
Debt and Credit Agreement	Debt and Credit Agreement 2016 Senior Secured Credit Facility On January 5, 2016, the Company entered into a $400 million senior secured credit facility pursuant to a credit agreement, by and among the Company, the lenders from time to time party thereto, Wells Fargo Securities, LLC, as Sole Lead Arranger and Wells Fargo Bank, National Association, as administrative agent (the “Credit Agreement”). The Credit Agreement provides for (a) a five -year revolving credit facility of $200 million (the “Revolving Credit Facility”) and (b) a five -year $200 million term loan facility (the “Term Loan Facility” and together with the Revolving Credit Facility, the “Facilities”). In addition, the Credit Agreement includes a letter of credit sub-limit of up to $10 million and a swing line loan sub-limit of up to $10 million . The Credit Agreement expires on January 5, 2021, upon which date all remaining outstanding borrowings are due and payable. Loans under the Facilities bear interest, at the Company’s option, at a rate equal to either (a) the LIBOR Rate, plus an applicable margin ranging from 1.50% to 2.25% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50% , and (iii) LIBOR for an interest period of one month, plus an applicable margin ranging from 0.50% to 1.25% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the 2016 Credit Agreement). Undrawn commitments under the Revolving Credit Facility will be subject to a commitment fee ranging from 0.20% to 0.35% per annum based on the Company’s Consolidated Total Net Leverage Ratio on the average daily unused portion of the Revolving Credit Facility. A letter of credit participation fee ranging from 1.50% to 2.25% per annum based on the Company’s Consolidated Total Net Leverage Ratio will accrue on the average daily amount of letter of credit exposure. The Company is permitted to make voluntary prepayments at any time without payment of a premium or penalty, except for any amounts relating to the LIBOR breakage indemnity described in the Credit Agreement. The Company is required to make mandatory prepayments under the Term Loan Facility with (a) net cash proceeds from any issuances of debt (other than certain permitted debt) and (b) net cash proceeds from certain asset dispositions (other than certain asset dispositions) and insurance and condemnation events (subject to reinvestment rights and certain other exceptions). Loans under the Term Loan Facility will amortize in quarterly installments, equal to 5% per annum of the original principal amount thereof during the first two years, which shall increase to 10% per annum during the third and fourth years, and 15% per annum during the fifth year, with the remaining balance payable on January 5, 2021. The Company is required to make mandatory prepayments under the Revolving Credit Facility if at any time the aggregate outstanding principal amount of loans together with the total amount of outstanding letters of credit exceeds the aggregate commitments, with such mandatory prepayment to be equal to the amount of such excess. The Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends and other distributions. The Credit Agreement contains financial covenants that require the Company and its subsidiaries to not exceed a maximum consolidated total leverage ratio and maintain a minimum fixed charge coverage ratio. The Company’s obligations under the Credit Agreement and any swap obligations and banking services obligations owing to a lender (or an affiliate of a lender) are guaranteed by certain of its domestic subsidiaries and secured by substantially all of its and the subsidiary guarantors’ assets. In connection with entering into the Credit Agreement, and as a condition precedent to borrowing loans thereunder, the Company and certain of the Company’s other direct and indirect subsidiaries have entered into certain ancillary agreements, including, but not limited to, a collateral agreement and subsidiary guaranty agreement. The Company was in full compliance with all covenants as of December 31, 2016 . On January 5, 2016, the Company borrowed the full $200 million under the Term Loan Facility and $55 million under the Revolving Credit Facility to complete the Aesynt acquisition and pay related fees and expenses. On December 2, 2016, the Company borrowed an additional $40 million under the Revolver Credit Facility to complete the Ateb acquisition and pay related fees and expenses. In connection with these Facilities, the Company incurred $7.9 million of debt issuance costs. The debt issuance costs were capitalized and presented as a direct deduction from the carrying amount of that debt liability in accordance with the accounting guidance. The debt issuance costs are being amortized to interest expense using the straight line method from issuance date through 2021. Interest expense was $5.3 million and $0 for the year ended December 31, 2016 and December 31, 2015, respectively. The components of the Company’s debt obligations as of December 31, 2016 and December 31, 2015 are as follows: December 31, 2015 Borrowings Repayment / Amortization December 31, 2016 (In thousands) Term loan facility $ — $ 200,000 $ (7,500 ) $ 192,500 Revolving credit facility — 95,000 (27,000 ) 68,000 Total debt under the facilities — 295,000 (34,500 ) 260,500 Less: Deferred issuance cost — (7,949 ) 1,590 (6,359 ) Total Debt, net of deferred issuance cost $ — $ 287,051 $ (32,910 ) $ 254,141 Long term debt, current portion, net of deferred issuance cost 8,410 Long term debt, net of deferred issuance cost $ 245,731 As of December 31, 2016 , the carrying amount, net of deferred issuance cost of $254.1 million approximates the fair value of $256.5 million . The Company's debt facilities are classified as a Level 3 in the fair value hierarchy. The calculation of the fair value is based on a discounted cash flow model using observable market inputs and taking into consideration variables such as interest rate changes, comparable instruments, and long-term credit ratings. 2013 Credit Agreement In September 2013, the Company entered into a credit agreement (the "Credit Agreement") with Wells Fargo Bank, National Association, as administrative agent, and the lenders from time to time party thereto. The Credit Agreement provided for a $75.0 million revolving credit facility with a $10.0 million letter of credit sub-limit. Loans under the Credit Agreement had maturity date of September 25, 2018. The Credit Agreement permitted the Company to request one or more increases in the aggregate commitments provided that such increases do not exceed $25.0 million in the aggregate. The Company expected to use the proceeds from any revolving loans under the credit facility for general corporate purposes, including future acquisitions. The Company's obligations under the Credit Agreement were guaranteed by certain of its domestic subsidiaries and secured by substantially all of the Company's and the subsidiary guarantors’ assets. The Company had not drawn any funds under the credit facility as of December 31, 2015 . On January 5, 2016, this Credit Agreement was replaced by the credit facilities discussed above.

Deferred Revenue

Deferred Revenue	12 Months Ended
Deferred Revenue	Dec. 31, 2016
Deferred Revenue Disclosure [Abstract]
Deferred Revenue	Deferred Revenue Short-term deferred revenue includes deferred revenue from product sales and service contracts, net of deferred cost of sales of $14.2 million and $15.7 million as of December 31, 2016 and December 31, 2015 , respectively. The short-term deferred revenues from product sales relate to the delivered and invoiced products, pending installation and acceptance, expected to occur within the next twelve months. Long-term deferred revenue includes deferred revenue from the service contracts of $ 17.1 million and $ 18.0 million , as of December 31, 2016 and December 31, 2015 , respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Lease commitments The Company leases office space and office equipment under operating leases. Commitments under operating leases primarily relate to leasehold property and office equipment. Rent expense was $9.8 million , $7.0 million and $6.8 million for the years ended December 31, 2016 , December 31, 2015 and December 31, 2014 , respectively. The minimum future payments on non-cancelable operating leases are as follows: For the year ended December 31, (In thousands) 2017 $ 11,300 2018 10,994 2019 10,995 2020 7,358 2021 6,719 Thereafter 10,326 Total minimum future lease payments $ 57,692 Purchase obligations During the course of the business, we issue purchase orders based on our current manufacturing needs. As of December 31, 2016 , the Company had non-cancelable purchase commitments of $ 42.9 million , which are expected to be paid within the next twelve months. Legal proceedings The Company is currently involved in various legal proceedings. As required under ASC 450, Contingencies , the Company accrues for contingencies when it believes that a loss is probable and that it can reasonably estimate the amount of any such loss. The Company has not recorded any accrual for contingent liabilities associated with the legal proceedings described below based on its belief that any potential loss, while reasonably possible, is not probable. Further, any possible range of loss in these matters cannot be reasonably estimated at this time. The Company believes that it has valid defenses with respect to legal proceedings pending against it. However, litigation is inherently unpredictable, and it is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of this contingency or because of the diversion of management's attention and the creation of significant expenses. The Company is not a party to any legal proceedings that management believes may have a material impact on the Company's financial position or results of operations. Guarantees As permitted under Delaware law and the Company's certificate of incorporation and bylaws, the Company has agreed to indemnify its directors and officers against certain losses that they may suffer by reason of the fact that such persons are, were or become its directors or officers. The term of the indemnification period is for the director’s or officer’s lifetime and there is no limit on the potential amount of future payments that the Company could be required to make under these indemnification agreements. The Company has purchased a directors’ and officers’ liability insurance policy that may enable it to recover a portion of any future payments that it may be required to make under these indemnification agreements. Assuming the applicability of coverage and the willingness of the insurer to assume coverage and subject to certain retention, loss limits and other policy provisions, the Company believes it is unlikely that the Company will be required to pay any material amounts pursuant to these indemnification obligations. However, no assurances can be given that the insurers will not attempt to dispute the validity, applicability or amount of coverage without expensive and time-consuming litigation against the insurers. Additionally, the Company undertakes indemnification obligations in its ordinary course of business in connection with, among other things, the licensing of its products and the provision of its support services. In the ordinary course of the Company's business, the Company has in the past and may in the future agree to indemnify another party, generally its business affiliates or customers, against certain losses suffered or incurred by the indemnified party in connection with various types of claims, which may include, without limitation, claims of intellectual property infringement, certain tax liabilities, its gross negligence or intentional acts in the performance of support services and violations of laws. The term of these indemnification obligations is generally perpetual. In general, the Company attempts to limit the maximum potential amount of future payments that it may be required to make under these indemnification obligations to the amounts paid to it by a customer, but in some cases the obligation may not be so limited. In addition, the Company has in the past and may in the future warrant to its customers that its products will conform to functional specifications for a limited period of time following the date of installation (generally not exceeding 30 days) or that its software media is free from material defects. Sales contracts for certain of the Company's medication packaging systems often include limited warranties for up to six months, but the periodic activity and ending warranty balances the Company records have historically been immaterial. From time to time, the Company may also warrant that its professional services will be performed in a good and workmanlike manner or in a professional manner consistent with industry standards. The Company generally seeks to disclaim most warranties, including any implied or statutory warranties such as warranties of merchantability, fitness for a particular purpose, title, quality and non-infringement, as well as any liability with respect to incidental, consequential, special, exemplary, punitive or similar damages. In some states, such disclaimers may not be enforceable. If necessary, the Company would provide for the estimated cost of product and service warranties based on specific warranty claims and claim history. The Company has not been subject to any significant claims for such losses and have not incurred any material costs in defending or settling claims related to these indemnification obligations. Accordingly, the Company believes it is unlikely that the Company will be required to pay any material amounts pursuant to these indemnification obligations or potential warranty claims and, therefore, no material liabilities have been recorded for such indemnification obligations as of December 31, 2016 and December 31, 2015 .

Employee Benefits and Share-Bas

Employee Benefits and Share-Based Compensation	12 Months Ended
Employee Benefits and Share-Based Compensation	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Employee Benefits and Share-Based Compensation	Employee Benefits and Share-Based Compensation Stock purchase plan 1997 Employee Stock Purchase Plan The Company has an Employee Stock Purchase Plan ("ESPP"), under which employees can purchase shares of its common stock based on a percentage of their compensation, but not greater than 15% of their earnings; provided, however, an eligible employee's right to purchase shares of the Company's common stock may not accrue at a rate which exceeds $25,000 of the fair market value of such shares for each calendar year in which such rights are outstanding. The purchase price per share must be equal to the lower of 85% of the fair value of the common stock at the beginning of a 24-month offering period or the end of each six-month purchasing period. At the Company's 2009 Annual Meeting of Stockholders (the "2009 Annual Meeting"), its stockholders approved an amendment to the ESPP, which added 2.6 million shares to the reserve for future issuance. At the Company's 2015 Annual Meeting of Stockholders (the "2015 Annual Meeting"), its stockholders approved an amendment to the ESPP, which added and additional 3.0 million shares to the reserve for future issuance. There was a total of 2.8 million shares reserved for future issuance under the ESPP as of December 31, 2016 . For the year ended December 31, 2016 , employees purchased 0.4 million shares of common stock under the ESPP and an aggregate of 5.5 million shares were issued under the ESPP as of December 31, 2016 . Stock award plans 2009 Equity Incentive Plan On May 19, 2009 , at the Company's 2009 Annual Meeting, the stockholders approved the Omnicell, Inc. 2009 Equity Incentive Plan, and as subsequently amended, (the "2009 Plan"). The 2009 Plan provides for the issuance of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards and other stock awards to the Company's employees, directors and consultants. The 2009 Plan succeeded the 1999 Equity Incentive Plan, the 2003 Equity Incentive Plan and the 2004 Equity Incentive Plan (collectively, the "Prior Plans"). No additional awards will be granted under any of the Prior Plans; however, all outstanding stock awards granted under the Prior Plans continue to be subject to the terms and conditions as set forth in the agreements evidencing such stock awards. On December 16, 2010, at a Special Meeting of Stockholders, the Company's stockholders approved an amendment to increase the number of shares of common stock authorized for issuance under the 2009 Plan by 2.6 million shares and to provide that the number of common stock shares available for issuance under the 2009 Plan be reduced by 1.8 shares for each share granted as a full-value award granted on and after October 1, 2010. For each share granted as a full-value award granted prior to October 1, 2010, future shares available for grants under the 2009 Plan were reduced by 1.4 shares. Awards granted as stock options and stock appreciation rights continue to reduce the number of shares available for issuance under the 2009 Plan on a one -for-one basis. At the Company's 2013 Annual Meeting of Stockholders, the Company's stockholders approved an amendment to the 2009 Plan to increase the number of shares of common stock authorized for issuance by 2.5 million shares. At the 2015 Annual Meeting, the Company's stockholders approved an amendment to the 2009 Plan to increase the number of shares of common stock authorized for issuance by 3.2 million shares and to provide that number of common stock shares available for issuance under the 2009 Plan be reduced by 2.15 shares for each share granted as a full value award on or after December 31, 2014. In addition, at the 2015 Annual Meeting, the Company's stockholders approved amendments to the 2009 Plan Stock providing that: (i) awards granted under the 2009 Plan will be subject to recoupment in accordance with any clawback policy that the Company may be required to adopt pursuant to applicable law and listing requirements and (ii) that the 2009 Plan will not expire by its terms but that no incentive stock options may be granted after the ten year anniversary of the earlier of the date that the 2009 Plan was adopted by the Company's Board of Directors or the date that the 2009 Plan was approved by its stockholders. There were 7.1 million shares of common stock reserved for future issuance under the 2009 Plan as of December 31, 2016 . Options granted under the 2009 Plan become exercisable over periods of up to four years , with one-fourth of the shares vesting one year from the vesting commencement date with respect to initial grants, and the remaining shares vesting in 36 equal monthly installments thereafter. The Company also grants both restricted stock and restricted stock units to participants under the 2009 Plan. Awards of restricted stock to non-employee directors are granted on the date of the annual meeting of stockholders and vest in full on the date of the next annual meeting of stockholders, provided such non-employee director remains a director on such date. The fair value of the award on the date of issuance is amortized to expense from the date of grant to the date of vesting. RSUs granted to employees vest over a period of four years and are expensed ratably on a straight-line basis over the vesting period. Performance-based Restricted Stock Units In 2011, the Company began incorporating performance-based restricted stock units ("PSUs") as an element of its executive compensation plans. In 2012, the Company granted 125,000 PSUs to its executive officers, of which 62,500 PSUs became eligible for vesting upon the achievement of a certain level of shareholder return. In 2013, the Company granted 137,500 PSUs to its executive officers all of which became eligible for vesting upon the achievement of a certain level of shareholder return. In 2014, the Company granted 132,500 PSUs to its executive officers, a portion became eligible for vesting upon the achievement of a certain level of shareholder return. In 2015, the Company granted 60,000 PSUs to its executive officers, all of which became eligible for vesting upon the achievement of a certain level of shareholder return. In 2016, the Company granted 122,740 PSUs to its executive officers, all, none or a portion of which may become eligible for vesting depending on the level of shareholder return for the period from March 1, 2016 through March 1, 2017. The fair value of a PSU award is determined using a Monte Carlo simulation model. The number of shares that vest at the end of the performance period depends on the percentile ranking of the total shareholder return for Omnicell stock over the performance period relative to the total shareholder return of each of the other companies in the NASDAQ Healthcare Index (the "Index"). Vesting for the PSUs is based both on the percentile placement of the Company's total stockholder return among the companies listed in the NASDAQ Health Care Index and time-based vesting. The Company calculates total stockholder return based on the one year annualized rates of return reflecting price appreciation plus reinvestment of dividends. For PSUs granted on February 4, 2016, stock price appreciation is calculated based on the trailing 20-day average stock price just prior the first trading day of March 2016, compared to the trailing 20 -day average stock price just prior the first trading day of March 2017. For PSUs granted on February 6, 2015, stock price appreciation is calculated based on the trailing 20-day average stock price just prior the first trading day of March 2015, compared to the trailing 20 -day average stock price just prior the first trading day of March 2016. On March 3, 2015, the Compensation Committee confirmed 74.4% as the percentile rank of the Company's 2014 total stockholder return. This resulted in 100% of the 2014 PSUs, or 132,500 shares, as eligible for further time-based vesting. The eligible performance based restricted stock unit awards will vest as follows: 25% of the eligible shares vested immediately on March 3, 2015 with the remaining eligible awards vesting in equal increments, semi-annually, over the subsequent three -year period beginning on June 15th and December 15th of the year after the date of grant and each subsequent year. Vesting is contingent upon continued service. Of the 132,500 shares eligible for time-based vesting under the 2014 PSUs 93,000 shares have vested as of December 31, 2016. On March 7, 2016, the Compensation Committee confirmed 66.0% as the percentile rank of the Company's 2016 total stockholder return. This resulted in 100% of the 2015 PSUs, or 60,000 shares, as eligible for further time-based vesting. The eligible performance based restricted stock unit awards will vest as follows: 25% of the eligible shares vested immediately on March 7, 2016 with the remaining eligible awards vesting in equal increments, semi-annually, over the subsequent three -year period beginning on June 15th and December 15th of the year after the date of grant and each subsequent year. Vesting is contingent upon continued service. Of the 60,000 shares eligible for time-based vesting under the 2015 PSUs, 30,000 shares have vested as of December 31, 2016. Valuation of share-based awards The following assumptions were used to value share options and ESPP shares granted pursuant to our equity incentive plans: Year Ended December 31, December 31, December 31, Stock Option Plans Risk-free interest rate 1.5 % 1.7 % 1.6 % Dividend yield — % — % — % Expected volatility 30.6 % 32.0 % 34.9 % Expected life (in years) 4.9 years 5.0 years 4.8 years Year Ended December 31, December 31, December 31, Employee Stock Purchase Plan Risk-free interest rate 0.34% - 0.79% 0.03% - 0.79% 0.03% - 0.53% Dividend yield — % — % — % Expected volatility 25.8% - 34.8% 25.7% - 37.5% 29.5% - 42.1% Expected life (in years) 0.5 - 2.0 0.5 - 2.0 0.5 - 2.0 Share-based compensation expense The Company accounts for share-based awards granted to employees and directors, including employee stock option awards, restricted stock, PSUs and RSUs issued pursuant to the 2009 Plan and employee stock purchases made under its ESPP using the estimate grant date fair value method of accounting in accordance with ASC 718, Stock Compensation . The Company values options and ESPP shares using the Black-Scholes-Merton option-pricing model. Restricted stock and time-based RSUs are valued at the grant date fair value of the underlying common shares. The PSUs are valued using the Monte Carlo simulation model. The following table sets forth the total share-based compensation expense recognized in the Company's Consolidated Statements of Income: Year Ended December 31, December 31, December 31, (In thousands) Cost of product and service revenues $ 2,596 $ 2,111 $ 1,456 Research and development 3,128 2,060 1,655 Selling, general and administrative 13,776 10,750 9,674 Total share-based compensation expense $ 19,500 $ 14,921 $ 12,785 The Company did not capitalize any share-based compensation as inventory as such amounts were not material for the years ended December 31, 2016 , December 31, 2015 and December 31, 2014 . Income tax benefits realized from share-based compensation were $5.4 million , $5.0 million and $4.5 million , for the years ended December 31, 2016 , December 31, 2015 and December 31, 2014 , respectively. Stock options activity A summary of the stock option activity under the 2009 Plan is presented below: Number of Shares Weighted-Average Exercise Price Weighted-Average Remaining Years Aggregate Intrinsic Value (In thousands, except per share data) Outstanding at December 31, 2015 2,688 $ 22.89 6.9 Granted (Awarded) 1,055 32.11 Exercised (Released) (406 ) 19.58 Expired (8 ) 30.43 Forfeited (115 ) 30.19 Outstanding at December 31, 2016 3,214 26.06 7.3 $ 26,331 Exercisable at December 31, 2016 1,487 20.23 5.4 20,459 Vested and expected to vest at December 31, 2016 and thereafter 3,007 25.66 7.2 $ 25,778 The weighted-average fair value per share of options granted during 2016 , 2015 and 2014 was $9.33 , $9.67 and $9.12 , respectively. The intrinsic value of options exercised during 2016 , 2015 and 2014 was $5.6 million , $11.3 million and $14.1 million , respectively. As of December 31, 2016 , total unrecognized compensation cost related to unvested stock options was $13.3 million , which is expected to be recognized over a weighted-average vesting period of 3.0 years . As of December 31, 2015 , total unrecognized compensation cost related to unvested stock options was $11.2 million , which is expected to be recognized over a weighted-average vesting period of 2.9 years . Restricted stock activity Summaries of the restricted stock activity under the 2009 Plan are presented below: Number of Shares Weighted-Average Grant Date Fair Value Weighted-Average Remaining Years Aggregate Intrinsic Value (In thousands, except per share data) Restricted Stock Units Non-vested at December 31, 2015 417 $ 28.49 1.6 Granted (Awarded) 289 32.58 Vested (Released) (179 ) 26.83 Forfeited (22 ) 28.37 Non-vested at December 31, 2016 505 31.42 1.6 $ 17,135 The weighted-average grant date fair value per share of Restricted Stock Units ("RSUs") granted during 2016 , 2015 and 2014 was $32.58 , $31.44 and $28.88 , respectively. The total fair value of RSUs that vested in 2016 , 2015 and 2014 was $4.8 million , $4.7 million and $3.2 million , respectively. As of December 31, 2016 , total unrecognized compensation cost related to RSUs was $12.8 million , which is expected to be recognized over the remaining weighted-average vesting period of 2.9 years . As of December 31, 2015 , total unrecognized compensation cost related to RSUs was $11.2 million , which is expected to be recognized over the remaining weighted-average vesting period of 2.9 years. Number of Shares Weighted-Average Grant Date Fair Value (In thousands, except per share data) Restricted Stock Awards Non-vested at December 31, 2015 31 $ 35.97 Granted (Awarded) 34 31.59 Vested (Released) (35 ) 35.45 Forfeited — — — Non-vested at December 31, 2016 30 $ 31.57 The weighted-average grant date fair value per share of Restricted Stock Awards ("RSAs") granted during 2016 , 2015 and 2014 was $31.59 , $36.05 and $26.42 , respectively. The total fair value of RSAs that vested in 2016 , 2015 and 2014 was $1.2 million , $1.1 million and $1.0 million , respectively. As of December 31, 2016 , total unrecognized compensation cost related to RSAs was $0.4 million , which is expected to be recognized over the remaining weighted-average vesting period of 0.4 years. As of December 31, 2015 , total unrecognized compensation cost related to RSAs was $0.4 million , which was expected to be recognized over the remaining weighted-average vesting period of 0.4 years . Performance-based restricted stock unit activity A summary of the performance-based restricted stock activity under the 2009 Plan is presented below: Number of Shares Weighted-Average Grant Date Fair Value Per Unit (In thousands, except per share data) Non-vested at December 31, 2015 151 $ 23.33 Granted (Awarded) 123 24.66 Vested (Released) (90 ) 21.95 Forfeited — — Nov-vested at December 31, 2016 184 $ 24.89 The weighted-average grant date fair value per share of PSUs granted during 2016 , 2015 and 2014 was $24.66 , $29.56 and $20.94 , respectively. The total fair value of PSUs that vested in 2016 , 2015 and 2014 was $2.0 million , $1.9 million and $1.5 million , respectively. As of December 31, 2016 , total unrecognized compensation cost related to PSUs was approximately $1.6 million , which is expected to be recognized over the remaining weighted-average period of 1.2 years. As of December 31, 2015 , total unrecognized compensation cost related to PSUs was approximately $1.5 million , which was expected to be recognized over the remaining weighted-average period of 1.2 years. Employee Stock Purchase Plan The unrecognized compensation cost related to the shares to be purchased under the ESPP was approximately $3.5 million , and is expected to be recognized over a weighted-average period of 1.2 years as of December 31, 2016 . Summary of Shares Reserved for Future Issuance under Equity Incentive Plans The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of December 31, 2016 : Number of Shares (In thousands) Share options outstanding 3,214 Non-vested restricted stock awards 719 Shares authorized for future issuance 3,143 ESPP shares available for future issuance 2,831 Total shares reserved for future issuance 9,907 401(k) Plan The Company has established a pre-tax savings plan under Section 401(k) of the Internal Revenue Code. The 401(k) Plan allows eligible employees in the United States to voluntarily contribute a portion of their pre-tax salary, subject to a maximum limit specified in the Internal Revenue Code. The Company matches 50% of employee contributions up to $2,000 , annually. The Company's contributions under this plan were $1.9 million , $1.8 million and $1.3 million in 2016 , 2015 and 2014 , respectively.

Stock Repurchases

Stock Repurchases	12 Months Ended
Stock Repurchases	Dec. 31, 2016
Equity [Abstract]
Stock Repurchases	Stock Repurchases On August 2, 2016, the Board of Directors (the "Board") of the Company authorized a stock repurchase program providing for the repurchase of up to $50.0 million of the Company’s common stock (the “2016 Repurchase Program”). The 2016 Repurchase Program is in addition to the stock repurchase program approved by the Board on November 4, 2014 (the “2014 Repurchase Program”). As of December 31, 2016, the maximum dollar value of shares that may yet be purchased under the two repurchase programs was $54.9 million . The timing, price and volume of repurchases are to be based on market conditions, relevant securities laws and other factors. The stock repurchases may be made from time to time on the open market, in privately negotiated transactions or pursuant to a Rule 10b-18 plan, subject to the terms and conditions of that certain Credit Agreement, dated as of January 5, 2016, among the Company, the Lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent. The stock repurchase program does not obligate the Company to repurchase any specific number of shares, and the Company may terminate or suspend the repurchase program at any time. During the twelve months ended December 31, 2016 the Company made no repurchases of its outstanding common stock. The following table summarizes the Company's stock repurchases during the twelve months ended December 31, 2015 and December 31, 2014, respectively: December 31, December 31, (In thousands, except per share data) Total number of shares repurchased 1,424 884 Dollar amount of shares repurchased $ 50,021 $ 24,091 Average price paid per share $ 35.13 $ 27.24

Segment and Geographical Inform

Segment and Geographical Information	12 Months Ended
Segment and Geographical Information	Dec. 31, 2016
Segment Reporting [Abstract]
Segment and Geographical Information	Segment and Geographical Information Segment Information The Company's Chief Operating Decision Maker ("CODM") is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company's segments using information about its revenues, gross profit, and income from operations. Such evaluation excludes general corporate-level costs that are not specific to either of the reportable segments and are managed separately at the corporate level. Corporate-level costs include expenses related to executive management, finance and accounting, human resources, legal, training and development, and certain administrative expenses. The two operating segments, which are the same as the Company's two reportable segments, are as follows: Automation and Analytics The Automation and Analytics segment is organized around the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems, and related software. The Automation and Analytics products are designed to enable the Company's customers to enhance and improve the effectiveness of the medication-use process, the efficiency of the medical-surgical supply chain, overall patient care and clinical and financial outcomes of medical facilities. Through modular configuration and upgrades, the Company's systems can be tailored to specific customer needs. The financial results of Aesynt acquired in the first quarter of 2016 are included in the Automation and Analytics segment. Medication Adherence The Medication Adherence segment includes primarily the manufacturing and selling of consumable medication blister cards, packaging equipment and ancillary products and services. These products are used to manage medication administration outside of the hospital setting and include medication adherence products, which consist of proprietary medication packaging systems and related products for use by institutional pharmacies servicing long-term care, and correctional facilities or retail pharmacies serving patients in their local communities. The financial results of Ateb acquired in the fourth quarter of 2016 are included in the Medication Adherence segment. The historical information presented has been retrospectively adjusted to reflect the new segment reporting. The following table summarizes the financial performance of the Company's reporting segments: Year Ended December 31, 2016 December 31, 2015 December 31, 2014 Automation and Analytics (2) Medication (2) Total Automation and Analytics (1) Medication Adherence (2) Total Automation and Analytics Medication Adherence Total (In thousands) Revenues $ 593,626 $ 98,997 $ 692,623 $ 390,321 $ 94,238 $ 484,559 $ 354,095 $ 86,805 $ 440,900 Cost of revenues 310,967 67,856 378,823 171,943 64,686 236,629 151,327 55,713 207,040 Gross profit 282,659 31,141 313,800 218,378 29,552 247,930 202,768 31,092 233,860 Operating expenses 198,511 24,843 223,354 114,084 24,258 138,342 105,929 20,586 126,515 Income from operations $ 84,148 $ 6,298 90,446 $ 104,294 $ 5,294 109,588 $ 96,839 $ 10,506 107,345 Corporate costs 83,965 60,956 57,762 Income from operations $ 6,481 $ 48,632 $ 49,583 _________________________________________________ (1) Includes Avantec and Mach4 results as of April 2015, the acquisition date. (2) Includes Aesynt and Ateb results as of January and December 2016, respectively, the acquisition dates. Significant customers There were no customers that accounted for more than 10% of the Company's total revenues in 2016, 2015 and 2014. Geographical Information Revenues Year Ended December 31, December 31, December 31, (In thousands) United States $ 591,566 $ 403,375 $ 394,234 Rest of world (1) 101,057 81,184 46,666 Total revenues $ 692,623 $ 484,559 $ 440,900 ______________________________________________ (1) No individual country represented more than 10% of the respective totals. Property and equipment, net December 31, December 31, December 31, (In thousands) United States $ 36,497 $ 29,506 $ 35,335 Rest of world (1) 5,514 2,803 843 Total property and equipment, net $ 42,011 $ 32,309 $ 36,178 _________________________________________________ (1) No individual country represented more than 10% of the respective totals. Property and equipment, net is attributed to the geographic location in which it is located.

Income Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The following is a geographical breakdown of income before the provision for (benefit from) income taxes: Year Ended December 31, December 31, December 31, (In thousands) Domestic $ 1,471 $ 51,089 $ 48,327 Foreign (3,419 ) (4,845 ) 177 Income before provision for (benefit from) income taxes $ (1,948 ) $ 46,244 $ 48,504 The provision for (benefit from) income taxes consists of the following: Year Ended December 31, December 31, December 31, (In thousands) Current: Federal $ 6,724 $ 13,840 $ 14,063 State 1,323 2,475 2,274 Foreign 46 203 192 Total current income taxes 8,093 16,518 16,529 Deferred: Federal (3,378 ) 846 1,603 State (1,802 ) (379 ) 84 Foreign (5,464 ) (1,501 ) (230 ) Total deferred income taxes (10,644 ) (1,034 ) 1,457 Total provision for (benefit from) income taxes $ (2,551 ) $ 15,484 $ 17,986 The provision for (benefit from) income taxes differs from the amount computed by applying the statutory federal tax rate as follows: Year Ended December 31, December 31, December 31, (In thousands) U.S. federal tax provision at statutory rate $ (682 ) $ 16,181 $ 16,998 State taxes (311 ) 1,365 1,533 Non-deductible expenses 1,212 551 809 Acquisition costs 845 239 229 Share-based compensation expense 1,941 748 461 Research tax credits (2,075 ) (1,324 ) (818 ) Domestic production deduction (890 ) (1,133 ) (1,127 ) Gain on investment — (1,205 ) — Tax audit settlement (2,499 ) — — Other (92 ) 62 (99 ) Total provision for (benefit from) income taxes $ (2,551 ) $ 15,484 $ 17,986 Significant components of the Company's deferred tax assets (liabilities) are as follows: December 31, December 31, (In thousands) Deferred tax assets (liabilities): Deferred revenue $ 5,857 $ 14,020 Stock compensation 6,451 6,034 Inventory related items 2,915 2,541 Tax credit carry forwards 4,871 2,579 Reserves and accruals 929 — Loss carry forwards 8,077 667 Other, net 847 697 Total net deferred tax assets 29,947 26,538 Intangibles (57,427 ) (28,213 ) Depreciation and amortization (20,071 ) (17,185 ) Reserves and accruals — (601 ) Other, net — — Total deferred tax liabilities (77,498 ) (45,999 ) Net deferred tax liabilities $ (47,551 ) $ (19,461 ) Deferred income tax assets (liabilities) are provided for temporary differences that will result in future tax deductions or future taxable income, as well as the future benefit of tax credit carry forwards. The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing temporary differences, projected future taxable income, tax planning strategies, and results of recent operations. On the basis of this evaluation, as of December 31, 2016 , no valuation allowances have been recorded in any jurisdiction. As of December 31, 2016 , the Company has an immaterial amount of state net operating loss carryforwards available for income tax purposes. For income tax purposes, the Company has federal and California research tax credits carryforwards of $1.7 million and $7.2 million , respectively. Federal research tax credit carry forwards from prior years will begin to expire in 2035. California credits are available indefinitely to reduce cash taxes otherwise payable. Pursuant to the requirements of ASC 718, the Company does not include unrealized stock option attributes as components of our gross deferred tax assets. The tax effected amount of gross unrealized net operating loss and business tax credit carry forwards excluded under ASC 718 for the year ended December 31, 2016 is $ 3.0 million . In general, it is the Company's practice and intention to reinvest the earnings of its non-U.S. subsidiaries in those operations. As of December 31, 2016 , the Company has not made a provision for U.S. federal income and state income taxes on accumulated and current earnings of $2.5 million related to certain foreign subsidiaries because these earnings are intended to be indefinitely reinvested in operations outside the U.S. If the Company expects to distribute those earnings in the form of dividends or otherwise, the Company would be subject to U.S. and state income taxes reported as a component of income tax expense, in the amount of $1.0 million . This amount may be reduced by any foreign tax credits available at the time of repatriation. The Company files income tax returns in the United States and various states and foreign jurisdictions. In the normal course of business, the Company is subject to examination by taxing authorities, including major jurisdictions as the United States, California, the United Kingdom and Germany. In 2012, the Company concluded audits by the IRS and the California Franchise Tax Board for years 2008 and 2009. However, all of the net operating loss and research credit carryforwards that may be used in future years are subject to adjustment, if and when utilized. As such the Company's U.S. federal and California tax years remain open from 1996 and 1992, respectively. During fiscal 2016, the IRS and the Company settled all outstanding items related to the audit of the Company's federal income tax returns for the fiscal years ended December 31, 2014. The aggregate change in the balance of gross unrecognized tax benefits, which excludes interest and penalties, for the three years ended December 31, 2016 is as follows: (In thousands) Year Ended December 31, 2013 7,974 Increases related to tax positions taken during a prior period 63 Decreases related to tax positions taken during the prior period (89 ) Increases related to tax positions taken during the current period 801 Decreases related to settlements — Decreases related to expiration of statute of limitations (264 ) Year Ended December 31, 2014 8,485 Increases related to tax positions taken during a prior period 37 Decreases related to tax positions taken during the prior period (895 ) Increases related to tax positions taken during the current period 1,807 Decreases related to settlements — Decreases related to expiration of statute of limitations (284 ) Year Ended December 31, 2015 9,150 Increases related to tax positions taken during a prior period 244 Decreases related to tax positions taken during the prior period (1,980 ) Increases related to tax positions taken during the current period 6,724 Decreases related to settlements (2,178 ) Decreases related to expiration of statute of limitations (344 ) Year Ended December 31, 2016 $ 11,616 As of December 31, 2016 the total amount of gross unrecognized tax benefits, if realized, would decrease the Company's tax expense by approximately $7.6 million . The Company recognizes interest and/or penalties related to uncertain tax positions in operating expenses, which for 2016 was immaterial. The Company does not believe there will be any material changes in its unrecognized tax positions over the next twelve months.

2016 Restructuring Expenses

2016 Restructuring Expenses	12 Months Ended
2016 Restructuring Expenses	Dec. 31, 2016
Restructuring and Related Activities [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	2016 Restructuring Expenses In second quarter of 2016, the Company integrated its Sales and Field organizations in North America to better serve its customers which resulted in a reduction in headcount of 36 employees. Accordingly, the Company incurred approximately $1.7 million of restructuring expenses in the year ended December 31, 2016 , based on agreements with terminated employees covering salary and benefit continuation. For the year ended December 31, 2016 , the Company made payments of $1.7 million and the restructuring program was concluded.

Subsequent Events

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On February 15, 2017, the Company announced its plan to reduce its workforce by approximately 100 full-time employees, expected to be substantially completed in the first quarter of 2017. In connection with this plan, the Company will close of the Company’s Nashville, Tennessee and Slovenia facilities. Accordingly, the Company will accrue approximately $8.0 million in 2017 for restructuring related expenses.

Schedule II Valuation and Quali

Schedule II Valuation and Qualifying Accounts	12 Months Ended
Schedule II Valuation and Qualifying Accounts	Dec. 31, 2016
Valuation and Qualifying Accounts [Abstract]
Schedule II Valuation and Qualifying Accounts	SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS Additions Balance at (1) Charged to (2) Debited (credited) to Other Accounts (3) Amount Written Off (4) Acquisition and translation adjustments (5) Balance at (1) (In thousands) Year ended December 31, 2014 Accounts receivable $ 490 $ 941 $ (60 ) $ (165 ) $ — $ 1,206 Investment in sales-type leases 167 — (5 ) — — 162 Total allowances deducted from assets $ 657 $ 941 $ (65 ) $ (165 ) $ — $ 1,368 Year ended December 31, 2015 Accounts receivable $ 1,206 $ 453 $ 28 $ (447 ) $ — $ 1,240 Investment in sales-type leases 162 (99 ) 106 — — 169 Total allowances deducted from assets $ 1,368 $ 354 $ 134 $ (447 ) $ — $ 1,409 Year ended December 31, 2016 Accounts receivable $ 1,240 $ 727 $ 77 $ (369 ) $ 3,121 $ 4,796 Investment in sales-type leases 169 85 — — — 254 Total allowances deducted from assets $ 1,409 $ 812 $ 77 $ (369 ) $ 3,121 $ 5,050 __________________________________________________ (1) Allowance for doubtful accounts. (2) Represents amounts charged to bad debt expense, increasing the allowance. (3) Represents amounts debited to trade accounts receivable as recoveries, increasing the allowance. (4) Represents amounts written-off from the allowance and trade accounts receivable. (5) Represents primarily purchase price adjustments and minor foreign currency translation adjustments.

Organization and Summary of S25

Organization and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Principles of consolidation	Principles of consolidation The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. GAAP and include all adjustments necessary for the fair presentation of the Company's consolidated financial position, results of operations and cash flows for the periods presented. The Consolidated Financial Statements include the Company's accounts as well as those of its wholly owned subsidiaries after the elimination of intercompany balances and transactions.
Reclassifications	Certain prior year amounts have been reclassified to conform to 2016 presentation. These reclassifications include; (i) provision for excess and obsolete inventories and provision for receivables allowance have been reclassified/combined with inventories and accounts receivable within net cash provided by operating activities in the Consolidated Statements of Cash Flows, and (ii) the deferred service revenue and deferred gross profit have been combined under deferred revenue, net.
Use of estimates	Use of estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company's Consolidated Financial Statements and accompanying Notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. The Company's critical accounting policies are those that affect its financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, accounts receivable and notes receivable from investment in sales-type leases, inventory valuation, capitalized software development costs, valuation and impairment of goodwill, purchased intangibles and long-lived assets, share-based compensation and accounting for income taxes.
Segment reporting change	Segment reporting The Company's Chief Operating Decision Maker ("CODM") is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company's segments using information about its revenues, gross profit, and income from operations. Such evaluation excludes general corporate-level costs that are not specific to either of the reportable segments and are managed separately at the corporate level. Corporate-level costs include expenses related to executive management, finance and accounting, human resources, legal, training and development, and certain administrative expenses. See Note 13, Segment and Geographical Information, for addition information on segment reporting. The operating results of the recently acquired Aesynt, Mach4 and Avantec businesses are included in the Company's Automation and Analytics reportable segment. The operating results of the recently acquired Ateb business is included in the Medication Adherence reportable segment.
Foreign currency translation and remeasurement	Foreign currency translation and remeasurement Most of the Company's foreign subsidiaries use the local currency of their respective countries as their functional currency. The Company translates the assets and liabilities of such non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Revenue and expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recorded as foreign currency translation adjustments and included in accumulated other comprehensive income in stockholders’ equity. The Company’s foreign subsidiaries that use the U.S. dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the end of each period, and inventories, property and non-monetary assets and liabilities at historical rates. Gains and losses from such foreign currency remeasurement is recorded in interest and other income (expense). Foreign Currency Risk Management The Company operates in foreign countries, which expose it to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, the most significant of which is the British Pound and Euro. In order to manage foreign currency risk, at times the Company enters into foreign exchange forward contracts to mitigate risks associated with changes in spot exchange rates of mainly non-functional currency denominated assets or liabilities of our foreign subsidiaries. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. By working only with major banks and closely monitoring current market conditions, the Company seeks to limit the risk that counterparties to these contracts may be unable to perform. The foreign exchange forward contracts are measured at fair value and reported as other current assets or accrued liabilities on the Consolidated Balance Sheets. The derivative instruments the Company uses to hedge this exposure are not designated as hedges. Any gains or losses on the foreign exchange forward contracts are recognized in earnings as Other Income/Expense in the period incurred in the Consolidated Statements of Operations. The Company does not enter into derivative contracts for trading purposes.
Revenue recognition	Revenue recognition The Company earns revenues from sales of our medication and medical and surgical supply automation systems along with consumables and related services, which are sold in the healthcare industry, our principal market. Revenues are reported net of discounts and rebates provided to its customers. The Company's customer arrangements typically include one or more of the following deliverables: Products. Software-enabled equipment that manages and regulates the storage and dispensing of pharmaceuticals, consumable blister cards and packaging equipment and other medical supplies. Software. Additional software applications that enable incremental functionality of its equipment. Installation. Installation of equipment as integrated systems at customers' sites. Post-installation technical support. Phone support, on-site service, parts and access to unspecified software upgrades and enhancements, if and when available. Professional services. Other customer services, such as training and consulting. The Company recognizes revenue when the earnings process is complete, based upon its evaluation of whether the following four criteria have been met: Persuasive evidence of an arrangement exists. The Company uses signed customer contracts and signed customer purchase orders as evidence of an arrangement for leases and sales. For service engagements, the Company uses a signed services agreement and a statement of work to evidence an arrangement. Delivery has occurred. Equipment and embedded software product delivery is deemed to occur upon successful installation and receipt of a signed and dated customer confirmation of installation letter, providing evidence that the Company has delivered what a customer ordered. In instances of a customer self-installation, product delivery is deemed to have occurred upon receipt of a signed and dated customer confirmation letter. If a sale does not require installation, the Company recognizes revenue on delivery of products to the customer, including transfer of title and risk of loss, assuming all other revenue criteria are met. For existing distributors, where installation of equipment training has been previously provided and the distributor is certified to install the Company's equipment at the end-user customer facility, the Company recognizes revenue from sales of products to the distributor upon shipment assuming all other revenue criteria are met, net of allowance for rights of return or refund. For new distributors, where the Company has not provided installation of equipment training, revenue on the sales of products to the distributor is deferred until the distributor has completed the Distributor Training Program and has been certified to install the Company's equipment at the end-user facility. For the sale of consumable blister cards, the Company recognizes revenue when title and risk of loss of the products shipped have transferred to the customer, which usually occurs upon shipment from the Company's facilities. Assuming all other revenue criteria are met, the Company recognizes revenue for support services ratably over the related support services contract period. The Company recognizes revenue on training and professional services as they are performed. Fee is fixed or determinable. The Company assesses whether a fee is fixed or determinable at the outset of the arrangement based on the payment terms associated with the transaction. The Company has established a history of collecting under the original contract without providing concessions on payments, products or services. Collection is probable. The Company assesses the probability of collecting from each customer at the outset of the arrangement based on a number of factors, including the customer's payment history and its current creditworthiness. If, in the Company's judgment, collection of a fee is not probable, the Company defers revenue recognition until the uncertainty is removed, which generally means revenue is recognized upon the Company's receipt of cash payment assuming all other revenue criteria are met. The Company's historical experience has been that collection from its customers is generally probable. In arrangements with multiple deliverables, assuming all other revenue criteria are met, the Company recognizes revenue for individual delivered items if they have value to the customer on a standalone basis. The Company allocates arrangement consideration at the inception of the arrangement to all deliverables using the relative selling price method. This method requires the Company to determine the selling price at which each deliverable could be sold if it were sold regularly on a standalone basis. When available, the Company uses vendor-specific objective evidence ("VSOE") of the selling price. VSOE represents the price charged for a deliverable when it is sold separately, or for a deliverable not yet being sold separately, the price established by management with the relevant authority. The Company considers VSOE to exist when approximately 80% or more of its standalone sales of an item are priced within a reasonably narrow pricing range (plus or minus 15% of the median rates). The Company has established VSOE of the selling price for its post-installation technical support services and professional services. When VSOE of selling price is not available, third-party evidence ("TPE") of selling price for similar products and services is acceptable; however, the Company's offerings and market strategy differ from those of its competitors, such that it cannot obtain sufficient comparable information about third parties' prices. If neither VSOE nor TPE are available, the Company uses its best estimates of selling prices ("BESP"). The Company determines BESP considering factors such as market conditions, sales channels, internal costs and product margin objectives and pricing practices. The Company regularly reviews and updates its VSOE and BESP information. The relative selling price method allocates total arrangement consideration proportionally to each deliverable on the basis of its estimated selling price. In addition, the amount recognized for any delivered items cannot exceed that which is not contingent upon delivery of any remaining items in the arrangement. The Company also uses the residual method to allocate revenue between the software products that enable incremental equipment functionality, and thus are not deemed to deliver its essential functionality, and the related post-installation technical support, as these products and services continue to be accounted for under software revenue recognition rules. Under the residual method, the amount allocated to the undelivered elements equals VSOE of fair value of these elements. Any remaining amounts are attributed to the delivered items and are recognized when those items are delivered. A portion of the Company's sales are made through multi-year lease agreements. Under sales-type leases, the Company recognizes revenue for its hardware and software products net of lease execution costs such as post-installation product maintenance and technical support, at the net present value of the lease payment stream once its installation obligations have been met. The Company optimizes cash flows by selling a majority of its non-U.S. government leases to third-party leasing finance companies on a non-recourse basis. The Company has no obligation to the leasing company once the lease has been sold. Some of the Company's sales-type leases, mostly those relating to U.S. government hospitals which comprise approximately 45% of the lease receivable balance, are retained in-house. Interest income in these leases is recognized in product revenue using the effective interest method.
Cash equivalents	Cash and Cash Equivalents and Fair Value of Financial Instruments. The Company classifies investments as cash equivalents if their original or remaining contractual maturity is three months or less at the date of purchase. Cash equivalents are carried at amounts that approximate fair value due to the short period of time to maturity. The Company's cash equivalents are maintained in demand deposit accounts with financial institutions of high credit quality, and are invested in institutional money market funds, short-term bank time deposits and similar short duration instruments with fixed maturities. The Company continuously monitors the credit worthiness of the financial institutions and institutional money market funds in which it invests. The Company has not experienced any credit losses from its cash investments.
Foreign currency forward contracts and Interest rate swap agreements	Foreign currency forward contracts. The Company enters into foreign currency forward contracts to protect its business from the risk that exchange rates may affect the eventual cash flows resulting from intercompany transactions between Omnicell and its foreign subsidiaries. These transactions primarily arise as a result of products manufactured in the United States ("U.S") and sold to foreign subsidiaries in U.S. dollars rather than the subsidiaries' functional currencies. These forward contracts are considered to be financial derivative instruments and are recorded at fair value. Changes in fair values of these financial derivative instruments are either recognized in other comprehensive income or net income depending on whether the derivative has been designated and qualifies as a hedging instrument. Interest rate swap agreements. During the second quarter of 2016, the Company entered into interest rate swap agreements. The interest rate swap agreements, at their inception, qualified for and were designated as cash flow hedging instruments. In accordance with the Derivatives and Hedging Topic of the Accounting Standards Codification ("ASC"), the Company records its interest rate swaps on its consolidated balance sheet at fair value. The effective portion of changes in fair value are recorded in accumulated other comprehensive loss and are subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings. Any ineffective portion is recognized in earnings. Both at inception and on a quarterly basis, the Company performs an effectiveness test. For further information regarding these interest rate swap agreements, please refer to Note 4, "Cash and Cash Equivalents and Fair Value of Financial Instruments".
Debt	Debt. The Company has entered into a Credit Agreement which provides for (a) a five-year revolving credit facility and (b) a five-year term loan facility (Facilities). The amount borrowed under these facilities is recorded at its carrying value at December 31, 2016. The fair value at December 31, 2016 approximates the carrying value.
Accounts receivable and notes receivable from investment in sales-type leases	Accounts receivable and notes receivable from investment in sales-type leases The Company actively manages its accounts receivable to minimize credit risk. The Company typically sells to customers for which there is a history of successful collection. New customers are subject to a credit review process, which evaluates that customer's financial position and ability to pay. The Company continually monitors and evaluates the collectability of its trade receivables based on a combination of factors. The Company records specific allowances for doubtful accounts when it becomes aware of a specific customer's impaired ability to meet its financial obligation to the Company, such as in the case of bankruptcy filings or deterioration of financial position. There were no significant customers that accounted for more than 10% of the Company's accounts receivable as of December 31, 2016 and December 31, 2015 . Uncollectible amounts are charged off against trade receivables and the allowance for doubtful accounts when the Company makes a final determination that there is no reasonable expectation of recovery. Estimates are used in determining the Company's allowances for all other customers based on factors such as current trends, the length of time the receivables are past due and historical collection experience. While the Company believes that its allowance for doubtful accounts receivable is adequate and that the judgment applied is appropriate, such estimated amounts could differ materially from what will actually be uncollectible in the future. The retained in-house leases discussed above are considered financing receivables. The Company's credit policies and its evaluation of credit risk and write-off policies are applied alike to trade receivables and the net investment in sales-type leases. For both, an account is generally past due after thirty days. The financing receivables also have customer-specific reserves for accounts identified for specific impairment and a non-specific reserve applied to the remaining population, based on factors such as current trends, the length of time the receivables are past due and historical collection experience. The retained in-house leases are not stratified by portfolio or class.
Sales of accounts receivable	Sales of accounts receivable The Company records the sale of its accounts receivables as "true sales" in accordance with accounting guidance for transfers and servicing of financial assets.
Inventory	Inventory Inventories for 2016 are stated at the lower of cost (utilizing standard costs, applying the first-in, first-out method) or net realizable value, defined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Cost elements included in inventory are direct labor and materials plus applied overhead. The Company routinely assesses on-hand inventory for timely identification and measurement of obsolete, slow-moving or otherwise impaired inventory. The Company writes down its inventory for estimated obsolescence, excess or unmarketable quantities equal to the difference between the cost of the inventory and its estimated market value based on assumptions about future demand and market conditions. If actual future demand or market conditions are less favorable than the Company projected, additional inventory write-downs may be required.
Property and equipment	Property and equipment Property and equipment less accumulated depreciation are stated at historical cost. The Company's expenditures for property and equipment primarily are for computer equipment and software used in the administration of its business, and for leasehold improvements to its leased facilities. The Company also develops molds and dies used in long-term manufacturing arrangements with suppliers and for production automation equipment used in the manufacturing of consumable blister card components. Depreciation and amortization of property and equipment are provided over their estimated useful lives, using the straight-line method, as follows: Computer equipment and related software 3 - 5 years Leasehold and building improvements Shorter of the lease term or the estimated useful life Furniture and fixtures 5 - 7 years Equipment 3 - 12 years Depreciation and amortization of property and equipment was $15.0 million , $12.8 million and $11.3 million for the years ended December 31, 2016 , December 31, 2015 and December 31, 2014 , respectively. The Company capitalizes costs related to computer software developed or obtained for internal use in accordance with ASC 350-40, Internal-Use Software . Software obtained for internal use has generally been enterprise-level business and finance software that the Company customizes to meet its specific operational needs. Costs incurred in the application development phase are capitalized and amortized over their useful lives, which is generally five years. Costs recognized in the preliminary project phase and the post-implementation phase are expensed as incurred.
Software development costs	Software development costs The Company capitalizes software development costs in accordance with ASC 985-20, Costs of Software to Be Sold, Leased, or Marketed , under which certain software development costs incurred subsequent to the establishment of technological feasibility may be capitalized and amortized over the estimated lives of the related products. The Company establishes feasibility when it completes a working model and amortizes development costs over the estimated lives of the related products ranging from three to five years. The Company capitalized software development costs of $14.3 million and $12.1 million which are included in other assets as of December 31, 2016 and December 31, 2015 , respectively. The Company recorded $7.1 million , $5.8 million and $4.4 million to cost of revenues for amortization of capitalized software development costs for the years ended December 31, 2016 , December 31, 2015 and December 31, 2014 , respectively. All development costs prior to the completion of a working model are recognized as research and development expense.
Deferred revenue	Deferred revenue Deferred revenue arise when customers have been billed and/or have received products and/or services in advance of revenue recognition. The Company's deferred revenue, net, presented as short term consists primarily of (i) unearned revenue on sale of equipment for which installation has not been completed, net of deferred cost of sales for such equipment, and (ii) the current portion of unearned service contracts for which revenue is recognized over their duration.
Business combinations	Business combinations The Company uses the acquisition method of accounting under the authoritative guidance on business combinations. Each acquired company’s operating results are included in the Company's Consolidated Financial Statements starting on the date of acquisition. The purchase price is equivalent to the fair value of consideration transferred. Tangible and identifiable intangible assets acquired and liabilities assumed as of the date of acquisition are recorded at the acquisition date fair value. Goodwill is recognized for the excess of purchase price over the net fair value of assets acquired and liabilities assumed. Amounts allocated to assets and liabilities are based upon fair values. Such valuations require management to make significant estimates and assumptions, especially with respect to the identifiable intangible assets. Management makes estimates of fair value based upon assumptions believed to be reasonable and that of a market participant. These estimates are based on historical experience and information obtained from the management of the acquired companies and the estimates are inherently uncertain. The separately identifiable intangible assets generally include customer relationships, technology, and trade names.
Goodwill and intangible assets	Goodwill and intangible assets Goodwill. The Company reviews goodwill for impairment on an annual basis on the first day of the fourth quarter of each year at the reporting unit level. The Company's reporting units are the same as its operating segments, which are Automation and Analytics and Medication Adherence. A qualitative assessment is initially made to determine whether it is necessary to perform quantitative testing. This initial assessment includes, among others, consideration of: (i) past, current and projected future earnings and equity; (ii) recent trends and market conditions; and (iii) valuation metrics involving similar companies that are publicly-traded and acquisitions of similar companies, if available. If this initial qualitative assessment indicates that it is more likely than not that impairment exists, or if the Company decides to bypass this option, it proceeds to a two-step impairment test. The first step ("Step 1") involves a comparison between the estimated fair values of the Company's reporting units with their respective carrying amounts including goodwill. The methods for estimating reporting unit values include asset and liability fair values and other valuation techniques, such as discounted cash flows and multiples of earnings or revenues. If the carrying value exceeds estimated fair value, there is an indication of potential impairment, and the second step is performed to measure the amount of impairment. The second step involves calculating an implied fair value of goodwill by measuring the excess of the estimated fair value of the reporting units over the aggregate estimated fair values of the individual assets less liabilities. If the carrying value of goodwill exceeds the implied fair value of goodwill, an impairment charge is recorded for the excess. To determine each reporting unit's fair value in the second step, the Company uses the income approach which is based on the estimated discounted future cash flows of that reporting unit. The estimated fair value of each reporting unit under the income approach is corroborated with the market approach, which measures the value of a business through an analysis of recent sales or offerings of a comparable entity. The Company also considers its market capitalization on the date of the analysis to ensure the reasonableness of the sum of its reporting units’ estimated fair value. The Company performed a Step 1 impairment analysis as of October 1, 2016 for its Medication Adherence reporting unit. The Company determined that the fair value of this reporting unit exceeded the carrying value by more than 25%, and thus no impairment was indicated. Additionally, the Company performed a Step 0 impairment assessment analysis as of October 1, 2016 for its Automation and Analytics reporting unit taking into consideration past, current and projected future earnings, recent trends and market conditions; and valuation metrics involving similar companies that are publicly-traded. Based on the result of this analysis it is more likely than not an impairment does not e xist. Intangible assets. In connection with the Company's acquisitions, it generally recognizes assets for customer relationships, technology and trade names. Intangible assets are carried at cost less accumulated amortization. Such amortization is provided on a straight-line basis or on an accelerated basis based on a pattern of economic benefit that is expected to be obtained over the estimated useful lives of the respective assets, generally from 1 to 30 years. Amortization for developed technology and backlog is recognized in cost of product revenues, and amortization for customer relationships, non-compete agreements, and trade names is recognized in selling, general and administrative expenses. The Company assesses the impairment of identifiable intangible assets whenever events or changes in circumstances indicate that an asset's carrying amount may not be recoverable. Recoverability of an asset is measured by the comparison of the carrying amount to the sum of the undiscounted estimated future cash flows the asset is expected to generate, offset by estimated future costs to dispose of the product to which the asset relates. If an asset is considered to be impaired, the amount of such impairment would be measured as the difference between the carrying amount of the asset and its fair value. The Company's cash flow assumptions are based on historical and forecasted future revenue, operating costs, and other relevant factors. Assumptions and estimates about the remaining useful lives of the Company's intangible assets are subjective and are affected by changes to its business strategies. If management’s estimates of future operating results change, or if there are changes to other assumptions, the estimate of the fair value of the Company's assets could change significantly. Such change could result in impairment charges in future periods, which could have a significant impact on the Company's operating results and financial condition.
Valuation of share-based awards	Valuation of share-based awards The Company accounts for share-based compensation in accordance with ASC 718, Stock Compensation ("ASC 718"). The Company recognizes compensation expense related to stock-based compensation based on the grant date estimated fair value. The Company amortizes the fair value of the employee stock awards on a straight-line basis over the requisite service period of the award, which is generally the vesting period. The Company estimates the fair value of stock-based compensation awards using the Black-Scholes option pricing model, which requires the following inputs: expected life, expected volatility, risk-free interest rate, expected dividend yield rate, exercise price, and closing price of its common stock on the date of grant. The expected volatility is based on a combination of historical and market-based implied volatility, and the expected life of the awards is based on the Company's historical experience of employee stock option exercises, including forfeitures. The valuation assumptions used in estimating the fair value of employee share-based awards may change in future periods. The Company calculates its pool of excess tax benefits available within additional paid-in capital in accordance with the provisions of ASC 718.
Accounting for income tax	Accounting for income taxes The Company records an income tax provision (benefit) for the anticipated tax consequences of the reported results of operations. In accordance with U.S. GAAP, the provision for (benefit from income taxes is computed using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities and for operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using the enacted tax rates in effect for the periods in which those tax assets and liabilities are expected to be realized or settled. In the event that these tax rates change, the Company will incur a benefit or detriment on its income tax expense in the period of change. If the Company were to determine that all or part of the net deferred tax assets are not realizable in the future, it will record a valuation allowance that would be charged to earnings in the period such determination is made. In accordance with ASC 740, Income Taxes , the Company recognizes the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The calculation of tax liabilities involves significant judgment in estimating the impact of uncertainties in the application of U.S. GAAP and complex tax laws. Resolution of these uncertainties in a manner inconsistent with management’s expectations could have a material impact on our financial condition and operating results.
Commissions	Commissions Sales commissions are incremental and directly related to customer sales contracts in which revenue is deferred. These commission costs are accrued and recorded in prepaid expenses upon execution of a non-cancelable customer contract and subsequently expensed in the period of revenue recognition.
Shipping costs	Shipping costs Outbound freight billed to customers is recorded as product revenue. The related shipping and handling costs are expensed as part of selling, general and administrative expense.
Recently adopted accounting standards and recently issued authoritative guidance	Recently adopted accounting standards In April 2015, the Financial Accounting Standards Board ("FASB") issued ASU No. 2015-03, Interest — Imputation of Interest (Subtopic 835-30) — Simplifying the Presentation of Debt Issuance Costs, that requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the debt liability. The guidance is effective for fiscal years beginning after December 15, 2015, and interim periods within those years, with retrospective application required along with certain disclosures about the change in accounting principle, including the effect of the change on the financial statement line items. As required under ASU 2015-03 the Company has presented the deferred issuance cost related to the debt facilities of $7.9 million as a reduction of the debt liability. Refer to Note 8, Debt and Credit Agreement, for additional information. In April 2015, the FASB issued ASU No. 2015-05 , Intangibles-Goodwill and Other-Internal-Use Software - Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement , which provides guidance on determining whether a cloud computing arrangement contains a software license. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The Company adopted ASU 2015-05 on a prospective basis beginning on January 1, 2016. The impact of ASU 2015-05 did not have a material impact on the Company's consolidated financial position or results of operations for the year ended December 31, 2016. In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory. This ASU changes the measurement principle for inventory from the lower of cost or market to lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. It applies to entities that measure inventory using a method other than last-in, first-out (LIFO) and the retail inventory method (RIM). The guidance is effective for fiscal years beginning after December 15, 2016. The Company adopted ASU 2015-11 on a prospective basis beginning on January 1, 2016. The impact of ASU 2015-11 did not have a material impact on the Company's consolidated financial position or results of operations for the year ended December 31, 2016. In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. T his ASU requires adjustments to provisional amounts that are identified during the measurement period of a business combination to be recognized in the reporting period in which the adjustment amounts are determined. An acquirer is no longer required to revise comparative information for prior periods as if the accounting for the business combination had been completed as of the acquisition date. The provisions of ASU 2015-16 are effective for reporting periods beginning after December 15, 2015. The adoption of this accounting standard update did not have a material impact on the Company's consolidated financial position or results of operations for the year ended December 31, 2016. Recently issued authoritative guidance In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"). Under the new guidance, an entity is required to recognize an amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The original effective date for the ASU would have required the Company to adopt the standard beginning in its first quarter of fiscal year 2017. In July 2015, the FASB voted to amend ASU 2014-09 by approving a one-year deferral of the effective date as well as providing the option to early adopt the standard on the original effective date. Additionally, during 2016 the FASB issued several final ASUs to provide clarifications for the new revenue standard. These final ASU's were issued in March 2016, ASU No. 2016-08, Principal versus Agent Considerations (Reporting Revenue Gross versus Net), in April 2016, ASU No. 2016-10, Identifying Performance Obligations and Licensing, in May 2016, ASU No. 2016-12, Narrow-Scope Improvements and Practical Expedients and in December 2016, ASU No. 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers. All of these amendments have the same effective date as Topic 606, the new revenue standard. Accordingly, the Company will adopt the standard in its first quarter of fiscal year 2018. The Company is currently in the process of assessing the impact of adopting this new guidance. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) . The FASB amended lease accounting requirements to begin recording assets and liabilities arising from leases on the balance sheet. The new guidance will also require significant additional disclosures about the amount, timing and uncertainty of cash flows from leases. This new guidance will be effective for us beginning on January 1, 2019 using a modified retrospective approach. The modified retrospective approach includes a number of optional practical expedients that entities may elect to apply. The Company is currently evaluating the impact ASU 2016-02 will have on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting . This ASU simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The provisions of ASU 2016-09 are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted for any entity in any interim or annual period. If an entity early adopts the amendments in an interim period, any adjustments are reflected as of the beginning of the fiscal year that includes that interim period. An entity that elects early adoption must adopt all of the amendments in the same period. The Company is currently in the process of evaluating the impact of the adoption of ASU 2016-09 on its consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments — Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments , that modifies or replaces existing models for trade and other receivables, debt securities, loans and certain other financial instruments. For instruments measured at amortized cost, including trade and lease receivables, loans and held-to-maturity debt securities, the standard will replace today’s “incurred loss” approach with an “expected loss” model. Entities will be required to estimate expected credit losses over the life of the instrument, considering available relevant information about the collectibility of cash flows, including information about past events, current conditions, and reasonable and supportable forecasts. The new guidance will be effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years and will be applied prospectively with a cumulative effect adjustment as of the beginning of the first reporting period for which the guidance is effective. Early adoption is permitted for annual periods beginning after December 15, 2018 and interim periods therein. The Company is currently evaluating the impact ASU 2016-13 will have on its consolidated financial statements. In October 2016, the FASB issued ASU No. 2016-16 , Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory, which reduces the complexity in the accounting standards by allowing the recognition of current and deferred income taxes for an intra-entity asset transfer, other than inventory, when the transfer occurs. Historically, recognition of the income tax consequence was not recognized until the asset was sold to an outside party. This amendment should be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. ASU 2016-16 is effective for annual periods beginning after December 15, 2017, including interim reporting periods within those annual reporting periods. Early adoption is permitted for all entities as of the beginning of an annual reporting period for which financial statements (interim or annual) have not been issued or made available for issuance. The Company is currently evaluating the impact ASU 2016-16 will have on its consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business , which reduces the population of transactions that will be identified as businesses vs. assets for purposes of acquisition and disposal accounting. The standard provides an initial screen which excludes from the business definition any transaction where substantially all of the fair value is concentrated in a single (or group of similar) identifiable assets. Transactions which pass the initial screen must still contain inputs and a substantive process to meet the new business definition. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years, with prospective application. Early adoption is permitted. The Company is currently evaluating the impact ASU 2017-01 will have on its consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, Intangibles — Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment , that eliminates the requirement to calculate the implied fair value of goodwill (Step 2 of today’s goodwill impairment test) to measure a goodwill impairment charge. Instead, entities will record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (measure the charge based on today’s Step 1). There is no change to the optional Step 0 for qualitative assessment of impairment. ASU 2017-04 is effective for annual and interim impairment tests performed in periods beginning after December 15, 2019. Early adoption is permitted for annual and interim impairment dates after January 1, 2017. The Company is currently evaluating the impact ASU 2017-04 will have on its consolidated financial statements. In February 2017, the FASB issued ASU No. 2017-05, Other Income-Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20): Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets. This ASU clarifies the scope and application of ASC 610-20 on the sale or transfer of nonfinancial assets and in substance nonfinancial assets to noncustomers, including partial sales. The effective date of the ASU 2017-05 amendments to the nonfinancial asset guidance must coincide with the adoption of the ASU 2014-09 revenue standard (expected in the first quarter of fiscal year 2018), but the transition method does not have to be the same. Transition can use either the full retrospective approach or the modified retrospective approach. The Company is currently evaluating the impact ASU 2017-05 will have on its consolidated financial statements. There was no other recently issued and effective authoritative guidance that is expected to have a material impact on the Company's Consolidated Financial Statements through the reporting date.
Fair value	Fair value hierarchy The Company measures its financial instruments at fair value. The Company’s cash equivalents are classified within Level 1 of the fair value hierarchy as they are valued primarily using quoted market prices utilizing market observable inputs. The Company's interest rate swap contracts and foreign currency contracts are classified within Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments.
Guarantees	Guarantees As permitted under Delaware law and the Company's certificate of incorporation and bylaws, the Company has agreed to indemnify its directors and officers against certain losses that they may suffer by reason of the fact that such persons are, were or become its directors or officers. The term of the indemnification period is for the director’s or officer’s lifetime and there is no limit on the potential amount of future payments that the Company could be required to make under these indemnification agreements. The Company has purchased a directors’ and officers’ liability insurance policy that may enable it to recover a portion of any future payments that it may be required to make under these indemnification agreements. Assuming the applicability of coverage and the willingness of the insurer to assume coverage and subject to certain retention, loss limits and other policy provisions, the Company believes it is unlikely that the Company will be required to pay any material amounts pursuant to these indemnification obligations. However, no assurances can be given that the insurers will not attempt to dispute the validity, applicability or amount of coverage without expensive and time-consuming litigation against the insurers. Additionally, the Company undertakes indemnification obligations in its ordinary course of business in connection with, among other things, the licensing of its products and the provision of its support services. In the ordinary course of the Company's business, the Company has in the past and may in the future agree to indemnify another party, generally its business affiliates or customers, against certain losses suffered or incurred by the indemnified party in connection with various types of claims, which may include, without limitation, claims of intellectual property infringement, certain tax liabilities, its gross negligence or intentional acts in the performance of support services and violations of laws. The term of these indemnification obligations is generally perpetual. In general, the Company attempts to limit the maximum potential amount of future payments that it may be required to make under these indemnification obligations to the amounts paid to it by a customer, but in some cases the obligation may not be so limited. In addition, the Company has in the past and may in the future warrant to its customers that its products will conform to functional specifications for a limited period of time following the date of installation (generally not exceeding 30 days) or that its software media is free from material defects. Sales contracts for certain of the Company's medication packaging systems often include limited warranties for up to six months, but the periodic activity and ending warranty balances the Company records have historically been immaterial. From time to time, the Company may also warrant that its professional services will be performed in a good and workmanlike manner or in a professional manner consistent with industry standards. The Company generally seeks to disclaim most warranties, including any implied or statutory warranties such as warranties of merchantability, fitness for a particular purpose, title, quality and non-infringement, as well as any liability with respect to incidental, consequential, special, exemplary, punitive or similar damages. In some states, such disclaimers may not be enforceable. If necessary, the Company would provide for the estimated cost of product and service warranties based on specific warranty claims and claim history. The Company has not been subject to any significant claims for such losses and have not incurred any material costs in defending or settling claims related to these indemnification obligations. Accordingly, the Company believes it is unlikely that the Company will be required to pay any material amounts pursuant to these indemnification obligations or potential warranty claims and, therefore, no material liabilities have been recorded for such indemnification obligations as of December 31, 2016 and December 31, 2015 .

Organization and Summary of S26

Organization and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Property and Equipment	Depreciation and amortization of property and equipment are provided over their estimated useful lives, using the straight-line method, as follows: Computer equipment and related software 3 - 5 years Leasehold and building improvements Shorter of the lease term or the estimated useful life Furniture and fixtures 5 - 7 years Equipment 3 - 12 years

Business Combinations (Tables)

Business Combinations (Tables)	12 Months Ended
Business Combinations (Tables)	Dec. 31, 2016
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table represents the allocation of the purchase price to the assets acquired and the liabilities assumed by the Company during each acquisition, respectively, reconciled to the purchase price transferred included in the Company's Consolidated Balance Sheet: Aesynt Ateb (preliminary) Total (In thousands) Cash $ 8,164 $ 902 $ 9,066 Accounts receivable 43,312 7,905 51,217 Inventory 19,021 225 19,246 Other current assets 3,787 1,239 5,026 Total current assets 74,284 10,271 84,555 Property and equipment 10,389 2,447 12,836 Intangible assets 123,700 12,500 136,200 Goodwill 163,599 20,832 184,431 Other non-current assets 968 1,009 1,977 Total assets 372,940 47,059 419,999 Current liabilities 26,753 2,314 29,067 Deferred revenue, net 25,512 2,776 28,288 Non-current deferred tax liabilities 38,622 — 38,622 Other non-current liabilities 2,431 367 2,798 Total liabilities 93,318 5,457 98,775 Total purchase price 279,622 41,602 321,224 Total purchase price, net of cash received $ 271,458 $ 40,700 $ 312,158 Intangible assets acquired and their respective estimated remaining useful lives over which each asset will be amortized are as follows: Mach4 Avantec Fair value Weighted Fair value Weighted (In thousands) (In years) (In thousands) (In years) Developed technology $ 3,290 8 $ — — Trade name 850 6 92 2 Customer relationships 3,570 10 5,834 12 Backlog — — 415 2 Total purchased intangible assets $ 7,710 $ 6,341 Mach4 Avantec Total (In thousands) Cash $ 397 $ 3,392 $ 3,789 Accounts receivable 3,743 3,607 7,350 Inventory 3,580 1,428 5,008 Deferred tax assets and other current assets 368 89 457 Total current assets 8,088 8,516 16,604 Property and equipment 463 — 463 Intangibles 7,710 6,341 14,051 Goodwill 10,591 15,606 26,197 Other non-current assets 52 — 52 Total assets 26,904 30,463 57,367 Current liabilities 3,684 4,125 7,809 Non-current deferred tax liabilities 2,564 1,269 3,833 Deferred service revenue and gross profit 2,314 928 3,242 Other non-current liabilities 1,056 — 1,056 Total liabilities 9,618 6,322 15,940 Total purchase price 17,286 24,141 41,427 Total purchase price, net of cash received $ 16,889 $ 20,749 $ 37,638
Intangible Assets Acquired	The identifiable intangible assets acquired and their estimated useful lives for amortization are as follows: Aesynt Ateb (preliminary) Fair value Weighted Fair value Weighted (In thousands) (In years) (In thousands) (In years) Customer relationships $ 58,200 14-16 $ 8,900 12 Developed technology 38,800 8 3,400 5 Backlog 20,200 1-3 — - In-process research and development ("IPR&D") (1) 3,900 - — - Non-compete 1,800 3 100 1 Trade names 800 1 100 1 Total purchased intangible assets $ 123,700 $ 12,500 (1) The amortization of the in-process R&D assets begins when the in-process R&D projects are complete.
Business Acquisition, Pro Forma Information	The pro forma adjustments include the impact of fair value adjustment related to deferred revenue, inventory fair value adjustment, amortization of intangible assets, stock-based compensation expense, interest expense and amortization of deferred issuance cost, and certain classification to conform to Omnicell's accounting policies. Twelve months ended December 31, 2016 2015 (In thousands, except per share data) Pro forma net revenues $ 718,439 $ 522,317 Pro forma net income (loss) $ (1,330 ) $ 1,978 Pro forma net income (loss) per share $ (0.04 ) $ 0.05 Weighted average number of shares 36,156 36,699

Net Income Per Share (Tables)

Net Income Per Share (Tables)	12 Months Ended
Net Income Per Share (Tables)	Dec. 31, 2016
Earnings Per Share [Abstract]
Basic and Diluted Net Income Per Share	The calculation of basic and diluted net income per share is as follows: Year Ended December 31, December 31, December 31, (In thousands, except per share data) Net income $ 603 $ 30,760 $ 30,518 Weighted-average shares outstanding — basic 36,156 35,857 35,650 Add: Dilutive effect of employee stock plans 708 861 972 Weighted-average shares outstanding — diluted 36,864 36,718 36,622 Net income per share — basic $ 0.02 $ 0.86 $ 0.86 Net income per share — diluted $ 0.02 $ 0.84 $ 0.83 Anti-dilutive weighted-average shares related to stock award plans 1,345 555 640

Cash and Cash Equivalents and29

Cash and Cash Equivalents and Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Assets Measured at Fair Value On A Recurring Basis	Cash and cash equivalents at December 31, 2016 and December 31, 2015 were as follows: December 31, 2016 December 31, 2015 (In thousands) Cash $ 54,488 $ 72,103 Cash equivalents — 10,114 Total cash and cash equivalents $ 54,488 $ 82,217
Schedule of Financial Assets Measured at Fair Value	The following table represents the fair value hierarchy of the Company’s financial assets measured at fair value as of December 31, 2016 : Level 1 Level 2 Level 3 Total (In thousands) Interest rate swap contracts $ — $ 1,245 $ — $ 1,245 Total financial assets $ — $ 1,245 $ — $ 1,245 Contingent consideration liability $ — $ — $ 2,400 $ 2,400 Total financial liabilities $ — $ — $ 2,400 $ 2,400 The following table represents the fair value hierarchy of the Company’s financial assets measured at fair value as of December 31, 2015 : Level 1 Level 2 Level 3 Total (In thousands) Money market funds $ 10,114 $ — $ — $ 10,114 Forward contracts — 32 — 32 Total financial assets $ 10,114 $ 32 $ — $ 10,146 Contingent consideration liability $ — $ — $ 5,823 $ 5,823 Total financial Liabilities $ — $ — $ 5,823 $ 5,823

Balance Sheet Components (Table

Balance Sheet Components (Tables)	12 Months Ended
Balance Sheet Components (Tables)	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Balance Sheet	Balance sheet details as of December 31, 2016 and December 31, 2015 are presented in the tables below: December 31, December 31, (In thousands) Inventories: Raw materials $ 14,322 $ 11,582 Work in process 7,800 1,653 Finished goods 47,175 33,359 Total inventories $ 69,297 $ 46,594 Prepaid expenses Prepaid commissions $ 13,176 $ 9,240 Other prepaid expenses 15,470 10,346 Total prepaid expense $ 28,646 $ 19,586 Property and equipment: Equipment $ 64,384 $ 43,533 Furniture and fixtures 6,517 5,897 Leasehold improvements 9,778 9,063 Software 35,607 30,693 Construction in progress 7,211 3,651 Property and equipment, gross 123,497 92,837 Accumulated depreciation and amortization (81,486 ) (60,528 ) Total property and equipment, net $ 42,011 $ 32,309 Other long term assets: Capitalized software, net $ 33,233 $ 26,011 Other assets 1,818 1,883 Total other long term assets, net $ 35,051 $ 27,894 Accrued liabilities: Advance payments from customers $ 7,030 $ 8,327 Rebates and lease buyouts 4,025 4,702 Group purchasing organization fees 3,737 2,983 Taxes payable 4,003 2,768 Other accrued liabilities 12,400 11,353 Total accrued liabilities $ 31,195 $ 30,133
Schedule of Accumulated Other Comprehensive Income	The following table summarizes the changes in accumulated balances of other comprehensive income (loss) for the years ended December 31, 2016 and 2015 : Foreign currency translation adjustments Unrealized gain (loss) on interest rate swap hedges Total (In thousands) Balance as of December 31, 2014 $ (1,361 ) $ — $ (1,361 ) Other comprehensive income (loss) before reclassifications (1,369 ) — (1,369 ) Amounts reclassified from other comprehensive income (loss), net of tax — — — Net current-period other comprehensive income (loss), net of tax (1,369 ) — (1,369 ) Balance as of December 31, 2015 (2,730 ) — (2,730 ) Other comprehensive income (loss) before reclassifications (8,034 ) 1,385 (6,649 ) Amounts reclassified from other comprehensive income (loss), net of tax — (140 ) (140 ) Net current-period other comprehensive income (loss), net of tax (8,034 ) 1,245 (6,789 ) Balance as of December 31, 2016 $ (10,764 ) $ 1,245 $ (9,519 )

Net Investment in Sales-Type 31

Net Investment in Sales-Type Leases (Tables)	12 Months Ended
Net Investment in Sales-Type Leases (Tables)	Dec. 31, 2016
Leases [Abstract]
Schedule of Long Term Net Investment in Sale-Type Leases	The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at December 31, 2016 and December 31, 2015 : December 31, December 31, (In thousands) Net minimum lease payments to be received $ 33,591 $ 22,255 Less: unearned interest income portion (2,763 ) (1,014 ) Net investment in sales-type leases 30,828 21,241 Less: short-term portion (1) (10,243 ) (6,757 ) Long-term net investment in sales-type leases $ 20,585 $ 14,484 (1) The short-term portion of the net investments in sales-type leases is included in the other current assets on the Consolidated Balance Sheets.
Schedule of Financing Receivables, Minimum Payments	At December 31, 2016 , the future minimum lease payments to be received under sales-type leases are as follows: Year ended December 31, (In thousands) 2017 $ 11,172 2018 7,934 2019 6,240 2020 4,303 2021 2,396 Thereafter 1,546 Total $ 33,591

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
Goodwill and Intangible Assets (Tables)	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Carrying Amount of Goodwill	The changes in the carrying amount of goodwill are as follows: Automation and Analytics Medication Adherence Total (In thousands) Net balance as of December 31, 2014 $ 28,543 $ 94,177 $ 122,720 Additions (1) 26,197 — 26,197 Adjustments (2) (424 ) (587 ) (1,011 ) Net balance as of December 31, 2015 54,316 93,590 147,906 Additions (3) 163,599 20,832 184,431 Adjustments (2) (2,833 ) (1,780 ) (4,613 ) Net balance as of December 31, 2016 $ 215,082 $ 112,642 $ 327,724 _________________________________________________ (1) Additions to goodwill as a result of the Mach4 and Avantec acquisitions in April 2015, including a $0.1 million adjustment to the purchase price in the fourth quarter of 2015 for Mach4. (2) Adjustments reflect foreign currency exchange rate fluctuations. (3) Additions to goodwill as a result of the Aesynt acquisition in January 2016 and Ateb acquisition in December 2016.
Intangible Assets, Net	Intangible assets, net The carrying amounts of intangibles as of December 31, 2016 were as follows: December 31, 2016 Gross carrying amount Accumulated amortization Foreign currency exchange rate fluctuations Net carrying amount Useful life (years) (In thousands, except for years) Customer relationships $ 133,358 $ (20,930 ) $ (596 ) $ 111,832 1 - 30 Acquired technology 73,599 (13,287 ) (159 ) 60,153 3 - 20 Backlog 20,550 (14,083 ) — 6,467 1 - 3 Trade names 8,667 (3,887 ) (31 ) 4,749 1 - 12 Patents 3,154 (1,264 ) — 1,890 2 - 20 Non-compete agreements 1,900 (608 ) — 1,292 3 In process technology 3,900 — — 3,900 - Total intangibles assets, net $ 245,128 $ (54,059 ) $ (786 ) $ 190,283 The carrying amounts of intangibles as of December 31, 2015 were as follows: December 31, 2015 Gross carrying amount Accumulated amortization Foreign currency exchange rate fluctuations Net carrying amount Useful life (years) (In thousands, except for years) Customer relationships $ 69,554 $ (11,315 ) $ (719 ) $ 57,520 5 - 30 Acquired technology 30,870 (6,088 ) 59 24,841 3 - 20 Backlog 415 (163 ) (11 ) 241 2 Trade names 8,052 (2,551 ) (14 ) 5,487 1 - 12 Patents 1,960 (384 ) — 1,576 2 - 20 Total intangibles assets, net $ 110,851 $ (20,501 ) $ (685 ) $ 89,665
Future Amortization Expense for Intangible Assets	The estimated future amortization expenses for intangible assets are as follows: For the year ended December 31, (In thousands) 2017 $ 25,173 2018 22,840 2019 17,402 2020 16,255 2021 14,854 Thereafter (including IPR&D) 93,759 Total $ 190,283

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
Commitments and Contingencies (Tables)	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Minimum Future Rental on Non-Cancelable Operating Leases	The minimum future payments on non-cancelable operating leases are as follows: For the year ended December 31, (In thousands) 2017 $ 11,300 2018 10,994 2019 10,995 2020 7,358 2021 6,719 Thereafter 10,326 Total minimum future lease payments $ 57,692

Employee Benefits and Share-B34

Employee Benefits and Share-Based Compensation (Tables)	12 Months Ended
Employee Benefits and Share-Based Compensation (Tables)	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Estimate of Fair Value of Share-Based Awards, Stock Options	The following assumptions were used to value share options and ESPP shares granted pursuant to our equity incentive plans: Year Ended December 31, December 31, December 31, Stock Option Plans Risk-free interest rate 1.5 % 1.7 % 1.6 % Dividend yield — % — % — % Expected volatility 30.6 % 32.0 % 34.9 % Expected life (in years) 4.9 years 5.0 years 4.8 years
Estimate of Fair Value of Share-Based Awards, Employee Stock Purchase Plan	Year Ended December 31, December 31, December 31, Employee Stock Purchase Plan Risk-free interest rate 0.34% - 0.79% 0.03% - 0.79% 0.03% - 0.53% Dividend yield — % — % — % Expected volatility 25.8% - 34.8% 25.7% - 37.5% 29.5% - 42.1% Expected life (in years) 0.5 - 2.0 0.5 - 2.0 0.5 - 2.0
Share-Based Compensation Expense Recognized in Consolidate Statements of Income	The following table sets forth the total share-based compensation expense recognized in the Company's Consolidated Statements of Income: Year Ended December 31, December 31, December 31, (In thousands) Cost of product and service revenues $ 2,596 $ 2,111 $ 1,456 Research and development 3,128 2,060 1,655 Selling, general and administrative 13,776 10,750 9,674 Total share-based compensation expense $ 19,500 $ 14,921 $ 12,785
Stock Option Activity under the 2009 Plan	A summary of the stock option activity under the 2009 Plan is presented below: Number of Shares Weighted-Average Exercise Price Weighted-Average Remaining Years Aggregate Intrinsic Value (In thousands, except per share data) Outstanding at December 31, 2015 2,688 $ 22.89 6.9 Granted (Awarded) 1,055 32.11 Exercised (Released) (406 ) 19.58 Expired (8 ) 30.43 Forfeited (115 ) 30.19 Outstanding at December 31, 2016 3,214 26.06 7.3 $ 26,331 Exercisable at December 31, 2016 1,487 20.23 5.4 20,459 Vested and expected to vest at December 31, 2016 and thereafter 3,007 25.66 7.2 $ 25,778
Restricted Stock Units Activity under the 2009 Plan	Summaries of the restricted stock activity under the 2009 Plan are presented below: Number of Shares Weighted-Average Grant Date Fair Value Weighted-Average Remaining Years Aggregate Intrinsic Value (In thousands, except per share data) Restricted Stock Units Non-vested at December 31, 2015 417 $ 28.49 1.6 Granted (Awarded) 289 32.58 Vested (Released) (179 ) 26.83 Forfeited (22 ) 28.37 Non-vested at December 31, 2016 505 31.42 1.6 $ 17,135
Restricted Stock Units Award under the 2009 Plan	Number of Shares Weighted-Average Grant Date Fair Value (In thousands, except per share data) Restricted Stock Awards Non-vested at December 31, 2015 31 $ 35.97 Granted (Awarded) 34 31.59 Vested (Released) (35 ) 35.45 Forfeited — — — Non-vested at December 31, 2016 30 $ 31.57
Performance Shares Restricted Stock Activity under the 2009 Plan	A summary of the performance-based restricted stock activity under the 2009 Plan is presented below: Number of Shares Weighted-Average Grant Date Fair Value Per Unit (In thousands, except per share data) Non-vested at December 31, 2015 151 $ 23.33 Granted (Awarded) 123 24.66 Vested (Released) (90 ) 21.95 Forfeited — — Nov-vested at December 31, 2016 184 $ 24.89
Schedule of Share-based Compensation, Future Issuance of Shares	The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of December 31, 2016 : Number of Shares (In thousands) Share options outstanding 3,214 Non-vested restricted stock awards 719 Shares authorized for future issuance 3,143 ESPP shares available for future issuance 2,831 Total shares reserved for future issuance 9,907

Stock Repurchases (Tables)

Stock Repurchases (Tables)	12 Months Ended
Stock Repurchases (Tables)	Dec. 31, 2016
Equity [Abstract]
Stock Repurchases	The following table summarizes the Company's stock repurchases during the twelve months ended December 31, 2015 and December 31, 2014, respectively: December 31, December 31, (In thousands, except per share data) Total number of shares repurchased 1,424 884 Dollar amount of shares repurchased $ 50,021 $ 24,091 Average price paid per share $ 35.13 $ 27.24

Segment and Geographical Info36

Segment and Geographical Information (Tables)	12 Months Ended
Segment and Geographical Information (Tables)	Dec. 31, 2016
Segment Reporting [Abstract]
Financial Performance of Reporting Segments	The following table summarizes the financial performance of the Company's reporting segments: Year Ended December 31, 2016 December 31, 2015 December 31, 2014 Automation and Analytics (2) Medication (2) Total Automation and Analytics (1) Medication Adherence (2) Total Automation and Analytics Medication Adherence Total (In thousands) Revenues $ 593,626 $ 98,997 $ 692,623 $ 390,321 $ 94,238 $ 484,559 $ 354,095 $ 86,805 $ 440,900 Cost of revenues 310,967 67,856 378,823 171,943 64,686 236,629 151,327 55,713 207,040 Gross profit 282,659 31,141 313,800 218,378 29,552 247,930 202,768 31,092 233,860 Operating expenses 198,511 24,843 223,354 114,084 24,258 138,342 105,929 20,586 126,515 Income from operations $ 84,148 $ 6,298 90,446 $ 104,294 $ 5,294 109,588 $ 96,839 $ 10,506 107,345 Corporate costs 83,965 60,956 57,762 Income from operations $ 6,481 $ 48,632 $ 49,583 _________________________________________________ (1) Includes Avantec and Mach4 results as of April 2015, the acquisition date. (2) Includes Aesynt and Ateb results as of January and December 2016, respectively, the acquisition dates.
Revenue by Geographical Location	Revenues Year Ended December 31, December 31, December 31, (In thousands) United States $ 591,566 $ 403,375 $ 394,234 Rest of world (1) 101,057 81,184 46,666 Total revenues $ 692,623 $ 484,559 $ 440,900 ______________________________________________ (1) No individual country represented more than 10% of the respective totals.
Long-lived Assets by Geographic Areas	Property and equipment, net December 31, December 31, December 31, (In thousands) United States $ 36,497 $ 29,506 $ 35,335 Rest of world (1) 5,514 2,803 843 Total property and equipment, net $ 42,011 $ 32,309 $ 36,178 _________________________________________________ (1) No individual country represented more than 10% of the respective totals.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign	The following is a geographical breakdown of income before the provision for (benefit from) income taxes: Year Ended December 31, December 31, December 31, (In thousands) Domestic $ 1,471 $ 51,089 $ 48,327 Foreign (3,419 ) (4,845 ) 177 Income before provision for (benefit from) income taxes $ (1,948 ) $ 46,244 $ 48,504
Schedule of Components of Income Tax Expense (Benefit)	The provision for (benefit from) income taxes consists of the following: Year Ended December 31, December 31, December 31, (In thousands) Current: Federal $ 6,724 $ 13,840 $ 14,063 State 1,323 2,475 2,274 Foreign 46 203 192 Total current income taxes 8,093 16,518 16,529 Deferred: Federal (3,378 ) 846 1,603 State (1,802 ) (379 ) 84 Foreign (5,464 ) (1,501 ) (230 ) Total deferred income taxes (10,644 ) (1,034 ) 1,457 Total provision for (benefit from) income taxes $ (2,551 ) $ 15,484 $ 17,986
Schedule of Effective Income Tax Rate Reconciliation	The provision for (benefit from) income taxes differs from the amount computed by applying the statutory federal tax rate as follows: Year Ended December 31, December 31, December 31, (In thousands) U.S. federal tax provision at statutory rate $ (682 ) $ 16,181 $ 16,998 State taxes (311 ) 1,365 1,533 Non-deductible expenses 1,212 551 809 Acquisition costs 845 239 229 Share-based compensation expense 1,941 748 461 Research tax credits (2,075 ) (1,324 ) (818 ) Domestic production deduction (890 ) (1,133 ) (1,127 ) Gain on investment — (1,205 ) — Tax audit settlement (2,499 ) — — Other (92 ) 62 (99 ) Total provision for (benefit from) income taxes $ (2,551 ) $ 15,484 $ 17,986
Schedule of Deferred Tax Assets and Liabilities	Significant components of the Company's deferred tax assets (liabilities) are as follows: December 31, December 31, (In thousands) Deferred tax assets (liabilities): Deferred revenue $ 5,857 $ 14,020 Stock compensation 6,451 6,034 Inventory related items 2,915 2,541 Tax credit carry forwards 4,871 2,579 Reserves and accruals 929 — Loss carry forwards 8,077 667 Other, net 847 697 Total net deferred tax assets 29,947 26,538 Intangibles (57,427 ) (28,213 ) Depreciation and amortization (20,071 ) (17,185 ) Reserves and accruals — (601 ) Other, net — — Total deferred tax liabilities (77,498 ) (45,999 ) Net deferred tax liabilities $ (47,551 ) $ (19,461 )
Schedule of Unrecognized Tax Benefits	The aggregate change in the balance of gross unrecognized tax benefits, which excludes interest and penalties, for the three years ended December 31, 2016 is as follows: (In thousands) Year Ended December 31, 2013 7,974 Increases related to tax positions taken during a prior period 63 Decreases related to tax positions taken during the prior period (89 ) Increases related to tax positions taken during the current period 801 Decreases related to settlements — Decreases related to expiration of statute of limitations (264 ) Year Ended December 31, 2014 8,485 Increases related to tax positions taken during a prior period 37 Decreases related to tax positions taken during the prior period (895 ) Increases related to tax positions taken during the current period 1,807 Decreases related to settlements — Decreases related to expiration of statute of limitations (284 ) Year Ended December 31, 2015 9,150 Increases related to tax positions taken during a prior period 244 Decreases related to tax positions taken during the prior period (1,980 ) Increases related to tax positions taken during the current period 6,724 Decreases related to settlements (2,178 ) Decreases related to expiration of statute of limitations (344 ) Year Ended December 31, 2016 $ 11,616

Organization and Summary of S38

Organization and Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Apr. 30, 2015
Accounting Policies [Line Items]
Depreciation and amortization	$ 15,000,000	$ 12,800,000	$ 11,300,000
Vendor-Specific Objective Evidence (VSOE) exist when (approximately 80% or more) standalone sales are within a reasonable price range	80.00%
Transferred non-recourse accounts receivables	$ 28,700,000	38,600,000	62,000,000
Accounts receivables from third-party leasing companies for transferred non-recourse accounts receivables	200,000	800,000	1,100,000
Commissions expense	22,000,000	13,700,000	14,000,000
Wells Fargo Bank, National Association
Accounting Policies [Line Items]
Debt issuance cost, gross	$ 7,949,000
Internal use software and development costs
Accounting Policies [Line Items]
Useful life	5 years
Software and development costs to be sold
Accounting Policies [Line Items]
Cost of revenues for amortization of capitalized software development cost	$ 7,100,000	5,800,000	4,400,000
Minimum
Accounting Policies [Line Items]
Vendor-Specific Objective Evidence, within a reasonably narrow price range (plus or minus of median rate)	15.00%
Estimated useful lives of assets	1 year
Minimum \| Computer Equipment [Member]
Accounting Policies [Line Items]
Useful life	3 years
Minimum \| Furniture and Fixtures
Accounting Policies [Line Items]
Useful life	5 years
Minimum \| Equipment
Accounting Policies [Line Items]
Useful life	3 years
Maximum
Accounting Policies [Line Items]
Vendor-Specific Objective Evidence, within a reasonably narrow price range (plus or minus of median rate)	15.00%
Estimated useful lives of assets	30 years
Maximum \| Computer Equipment [Member]
Accounting Policies [Line Items]
Useful life	5 years
Maximum \| Furniture and Fixtures
Accounting Policies [Line Items]
Useful life	7 years
Maximum \| Equipment
Accounting Policies [Line Items]
Useful life	12 years
Selling, general and administrative
Accounting Policies [Line Items]
Shipping and handling expenses	$ 12,100,000	8,500,000	7,400,000
Capitalized software costs included in property and equipment \| Internal use software and development costs
Accounting Policies [Line Items]
Software development costs capitalized	2,200,000	1,200,000
Capitalized software costs included in other assets \| Software and development costs to be sold
Accounting Policies [Line Items]
Software development costs capitalized	14,300,000	12,100,000
Primary Supplier
Accounting Policies [Line Items]
Minimum supplier purchase obligations	$ 0
Notice of termination, time upon delivery	2 months
Payments to suppliers	$ 47,900,000	$ 41,700,000	$ 34,500,000
Credit Concentration Risk \| Lease Receivable
Accounting Policies [Line Items]
Percentage of lease receivable balance	45.00%
Avantec Heathcare Limited
Accounting Policies [Line Items]
Percentage of interest acquired				85.00%

Business Combinations - Additio

Business Combinations - Additional Information (Details) - USD ($) $ in Thousands	Dec. 08, 2016	Jan. 05, 2016	Apr. 30, 2015	Apr. 21, 2015	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2017	Apr. 29, 2014
Acquired Finite-Lived Intangible Assets [Line Items]
Purchase price of acquisition						$ 312,158	$ 25,507	$ 20,723
Goodwill					$ 147,906	327,724	147,906	122,720
Goodwill, purchase accounting adjustments						1,200
Provisional accounting, accounts receivable						1,600
Provisional accounting, inventory						1,100
Business Combiinations, Provisional Information, Initial Accounting Incomplete, Adjustment for Other Assetsa and Liabilities						(3,900)
Amortization of intangible assets						36,100	6,900	4,600
Gain related to contingent liability						600	0	0
Difference between fair value and carrying value as a gain						0	3,443	$ 0
Avantec
Acquired Finite-Lived Intangible Assets [Line Items]
Percentage of minority interest										15.00%
Carrying book value of previous equity interest			$ 1,300
Aesynt Holding, L.P., Aesynt, Ltd.
Acquired Finite-Lived Intangible Assets [Line Items]
Purchase price of acquisition						271,500
Cash acquired from Acquisition						8,200
Goodwill						163,599
Business Combination, Acquisition Related Costs		$ 9,300			2,900	6,400
Revenues						155,800
Operating Income (Loss)						40,500
Amortization of intangible assets						27,300
Total purchase price						$ 279,622
Aesynt Holding, L.P., Aesynt, Ltd. \| In-process research and development
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value inputs, royalty rate		12.50%
Aesynt Holding, L.P., Aesynt, Ltd. \| Trade name
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value inputs, royalty rate		0.50%
Aesynt Holding, L.P., Aesynt, Ltd. \| Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value inputs, discount rate		13.00%
Aesynt Holding, L.P., Aesynt, Ltd. \| Backlog
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value inputs, discount rate		10.00%
Aesynt Holding, L.P., Aesynt, Ltd. \| Non-compete
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value inputs, discount rate		13.00%
Aesynt Holding, L.P., Aesynt, Ltd. \| Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Research and Development Acquired In Process, Expected Term		3 years
Aesynt Holding, L.P., Aesynt, Ltd. \| Maximum \| Developed technology
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value inputs, royalty rate						8.00%
Aesynt Holding, L.P., Aesynt, Ltd. \| Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Research and Development Acquired In Process, Expected Term		2 years
Aesynt Holding, L.P., Aesynt, Ltd. \| Minimum \| Developed technology
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value inputs, royalty rate						4.00%
Ateb
Acquired Finite-Lived Intangible Assets [Line Items]
Purchase price of acquisition						$ 40,700
Cash acquired from Acquisition						900
Goodwill						20,832
Business Acquisition, Transaction Costs						1,700
Revenues						1,700
Operating Income (Loss)						100
Amortization of intangible assets						300
Total purchase price						$ 41,602
Ateb \| Trade name
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value inputs, royalty rate						0.50%
Ateb \| Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value inputs, discount rate						15.00%
Ateb \| Non-compete
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value inputs, discount rate	15.00%
Ateb \| Maximum \| Developed technology
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value inputs, royalty rate						6.00%
Ateb \| Minimum \| Developed technology
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value inputs, royalty rate						5.00%
Mach4
Acquired Finite-Lived Intangible Assets [Line Items]
Purchase price of acquisition				$ 16,889
Goodwill				10,591
Goodwill, purchase accounting adjustments					100
Total purchase price				17,286
Amount placed in escrow fund for business acquisition				$ 2,700
Avantec
Acquired Finite-Lived Intangible Assets [Line Items]
Purchase price of acquisition			20,749
Goodwill			15,606
Total purchase price			$ 24,141
Period after closing date to settle indemnification and other claims			18 months
Percentage of interest acquired			85.00%
Potential earn-out payments			$ 5,600		$ 3,000	$ 3,000	$ 3,000
Earn out payments made						3,000
Business acquisition, amount withheld for indemnification			1,800			1,800
Gain related to contingent liability						$ 600
Fair value of equity investment			4,700
Difference between fair value and carrying value as a gain			3,400
Payments to acquire business, in cash			$ 12,000
Avantec \| Forecast
Acquired Finite-Lived Intangible Assets [Line Items]
Potential earn-out payments									$ 2,400

Business Combinations - Total P

Business Combinations - Total Purchase Price and Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	Apr. 30, 2015	Apr. 30, 2015	Apr. 21, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill				$ 327,724	$ 147,906	$ 122,720
Total purchase price, net of cash received				312,158	25,507	$ 20,723
Aesynt
Business Acquisition [Line Items]
Cash				8,164
Accounts receivable				43,312
Inventory				19,021
Other current assets				3,787
Total current assets				74,284
Property and equipment				10,389
Intangibles				123,700
Goodwill				163,599
Other non-current assets				968
Total assets				372,940
Current liabilities				26,753
Deferred revenue, net				25,512
Long-term deferred tax liabilities				38,622
Other non-current liabilities				2,431
Total liabilities				93,318
Total purchase price				279,622
Total purchase price, net of cash received				271,500
Ateb
Business Acquisition [Line Items]
Cash				902
Accounts receivable				7,905
Inventory				225
Other current assets				1,239
Total current assets				10,271
Property and equipment				2,447
Intangibles				12,500
Goodwill				20,832
Other non-current assets				1,009
Total assets				47,059
Current liabilities				2,314
Deferred revenue, net				2,776
Long-term deferred tax liabilities				0
Other non-current liabilities				367
Total liabilities				5,457
Total purchase price				41,602
Total purchase price, net of cash received				40,700
Aesynt and Ateb
Business Acquisition [Line Items]
Cash				9,066
Accounts receivable				51,217
Inventory				19,246
Other current assets				5,026
Total current assets				84,555
Property and equipment				12,836
Intangibles				136,200
Goodwill				184,431
Other non-current assets				1,977
Total assets				419,999
Current liabilities				29,067
Deferred revenue, net				28,288
Long-term deferred tax liabilities				38,622
Other non-current liabilities				2,798
Total liabilities				98,775
Total purchase price				321,224
Total purchase price, net of cash received				$ 312,158
Mach4
Business Acquisition [Line Items]
Cash			$ 397
Accounts receivable			3,743
Inventory			3,580
Deferred tax assets and other current assets			368
Total current assets			8,088
Property and equipment			463
Intangibles			7,710		7,710
Goodwill			10,591
Other non-current assets			52
Total assets			26,904
Current liabilities			3,684
Long-term deferred tax liabilities			2,564
Deferred service revenue and gross profit			2,314
Other non-current liabilities			1,056
Total liabilities			9,618
Total purchase price			17,286
Total purchase price, net of cash received			$ 16,889
Avantec
Business Acquisition [Line Items]
Cash	$ 3,392	$ 3,392
Accounts receivable	3,607	3,607
Inventory	1,428	1,428
Deferred tax assets and other current assets	89	89
Total current assets	8,516	8,516
Property and equipment	0	0
Intangibles	6,341	6,341			$ 6,341
Goodwill	15,606	15,606
Other non-current assets	0	0
Total assets	30,463	30,463
Current liabilities	4,125	4,125
Long-term deferred tax liabilities	1,269	1,269
Deferred service revenue and gross profit	928	928
Other non-current liabilities	0	0
Total liabilities	6,322	6,322
Total purchase price	24,141	24,141
Total purchase price, net of cash received		20,749
2015 Acquisitions Mach4 and Avantec [Member]
Business Acquisition [Line Items]
Cash	3,789	3,789
Accounts receivable	7,350	7,350
Inventory	5,008	5,008
Deferred tax assets and other current assets	457	457
Total current assets	16,604	16,604
Property and equipment	463	463
Intangibles	14,051	14,051
Goodwill	26,197	26,197
Other non-current assets	52	52
Total assets	57,367	57,367
Current liabilities	7,809	7,809
Long-term deferred tax liabilities	3,833	3,833
Deferred service revenue and gross profit	3,242	3,242
Other non-current liabilities	1,056	1,056
Total liabilities	15,940	15,940
Total purchase price	41,427	$ 41,427
Total purchase price, net of cash received	$ 37,638

Business Combinations - Identif

Business Combinations - Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Apr. 30, 2015	Apr. 21, 2015
Aesynt
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets	$ 123,700
Aesynt \| Customer relationships
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets	$ 58,200
Aesynt \| Customer relationships \| Minimum
Finite-Lived Intangible Assets [Line Items]
Weighted average useful life (in years)	14 years
Aesynt \| Customer relationships \| Maximum
Finite-Lived Intangible Assets [Line Items]
Weighted average useful life (in years)	16 years
Aesynt \| Developed technology
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets	$ 38,800
Weighted average useful life (in years)	8 years
Aesynt \| Backlog
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets	$ 20,200
Aesynt \| Backlog \| Minimum
Finite-Lived Intangible Assets [Line Items]
Weighted average useful life (in years)	1 year
Aesynt \| Backlog \| Maximum
Finite-Lived Intangible Assets [Line Items]
Weighted average useful life (in years)	3 years
Aesynt \| In-process research and development
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets	$ 3,900
Aesynt \| Non-compete
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets	$ 1,800
Weighted average useful life (in years)	3 years
Aesynt \| Trade name
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets	$ 800
Weighted average useful life (in years)	1 year
Ateb
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets	$ 12,500
Ateb \| Customer relationships
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets	$ 8,900
Weighted average useful life (in years)	12 years
Ateb \| Developed technology
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets	$ 3,400
Weighted average useful life (in years)	5 years
Ateb \| Non-compete
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets	$ 100
Weighted average useful life (in years)	1 year
Ateb \| Trade name
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets	$ 100
Weighted average useful life (in years)	1 year
Mach4
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets		$ 7,710		$ 7,710
Mach4 \| Customer relationships
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets		$ 3,570
Weighted average useful life (in years)		10 years
Mach4 \| Developed technology
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets		$ 3,290
Weighted average useful life (in years)		8 years
Mach4 \| Trade name
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets		$ 850
Weighted average useful life (in years)		6 years
Avantec
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets		$ 6,341	$ 6,341
Avantec \| Customer relationships
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets		$ 5,834
Weighted average useful life (in years)		12 years
Avantec \| Developed technology
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets		$ 0
Avantec \| Backlog
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets		$ 415
Weighted average useful life (in years)		2 years
Avantec \| Trade name
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets		$ 92
Weighted average useful life (in years)		2 years

Business Combinations - Pro For

Business Combinations - Pro Forma Information (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Business Combinations [Abstract]
Pro forma net revenues	$ 718,439	$ 522,317
Pro forma net income	$ (1,330)	$ 1,978
Pro forma net income per share diluted (in dollars per share)	$ (0.04)	$ 0.05
Pro Forma Weighted Average Number of Shares Outstanding, Diluted	36,156	36,699

Net Income Per Share (Details)

Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Earnings Per Share [Abstract]
Net income	$ 603	$ 30,760	$ 30,518
Weighted-average shares outstanding — basic	36,156	35,857	35,650
Add: Dilutive effect of employee stock plans	708	861	972
Weighted-average shares outstanding — diluted	36,864	36,718	36,622
Net income, basic (usd per share)	$ 0.02	$ 0.86	$ 0.86
Net income, diluted (usd per share)	$ 0.02	$ 0.84	$ 0.83
Anti-dilutive weighted-average shares related to stock award plans	1,345	555	640

Cash and Cash Equivalents and44

Cash and Cash Equivalents and Fair Value of Financial Instruments - Assets Measured at Fair Value On A Recurring Basis (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		$ 10,114
Payment for contingent consideration	$ 3,000	0	$ 0
Gain related to contingent liability	600	0	$ 0
Fair Value, Measurements, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash	54,488	72,103
Cash equivalents	0	10,114
Total cash and cash equivalents	54,488	$ 82,217
Avantec Heathcare Limited
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Payment for contingent consideration	3,000
Contingent consideration, accrued interest paid	200
Business Combinations, Contingent Liability, Before Gain Recgonition	3,000
Business Combination, Contingent Consideration, Liability	2,400
Gain related to contingent liability	$ 600

Cash and Cash Equivalents and45

Cash and Cash Equivalents and Fair Value of Financial Instruments - Financial Assets and Liabilities Measured At Fair Value (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds		$ 10,114
Forward contracts		32
Interest rate swap contracts	$ 1,245
Total financial assets	1,245	10,146
Total financial liabilities	2,400	5,823
Fair Value, Inputs, Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds		10,114
Forward contracts		0
Interest rate swap contracts	0
Total financial assets	0	10,114
Total financial liabilities	0	0
Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds		0
Forward contracts		32
Interest rate swap contracts	1,245
Total financial assets	1,245	32
Total financial liabilities	0	0
Fair Value, Inputs, Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds		0
Forward contracts		0
Interest rate swap contracts	0
Total financial assets	0	0
Total financial liabilities	2,400	5,823
Contingent consideration liability
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	2,400	5,823
Contingent consideration liability \| Fair Value, Inputs, Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	0	0
Contingent consideration liability \| Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	0	0
Contingent consideration liability \| Fair Value, Inputs, Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	$ 2,400	$ 5,823

Cash and Cash Equivalents and46

Cash and Cash Equivalents and Fair Value of Financial Instruments - Foreign Currency Risk Management (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Derivatives, Fair Value [Line Items]
Derivative, fair value, less than		$ 32
Interest rate swap contracts	$ 1,245
Foreign Exchange Forward
Derivatives, Fair Value [Line Items]
Derivative, notional amount	0	$ 400
Interest Rate Swap
Derivatives, Fair Value [Line Items]
Derivative, notional amount	$ 100,000
Derivative, fixed interest rate	0.80%
Interest rate swap contracts	$ 1,200
LIBOR \| Interest Rate Swap
Derivatives, Fair Value [Line Items]
Derivative, variable rate floor	0.00%

Balance Sheet Components (Detai

Balance Sheet Components (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Inventories:
Raw materials	$ 14,322	$ 11,582
Work in process	7,800	1,653
Finished goods	47,175	33,359
Total inventories, net	69,297	46,594
Prepaid expenses
Prepaid commissions	13,176	9,240
Other prepaid expenses	15,470	10,346
Prepaid expenses	28,646	19,586
Property and equipment:
Equipment	64,384	43,533
Furniture and fixtures	6,517	5,897
Leasehold improvements	9,778	9,063
Software	35,607	30,693
Construction in progress	7,211	3,651
Property and equipment, gross	123,497	92,837
Accumulated depreciation and amortization	(81,486)	(60,528)
Total property and equipment, net	42,011	32,309	$ 36,178
Other long term assets:
Capitalized software, net	33,233	26,011
Other assets	1,818	1,883
Total other long term assets, net	35,051	27,894
Accrued liabilities:
Advance payments from customers	7,030	8,327
Rebates and lease buyouts	4,025	4,702
Group purchasing organization fees	3,737	2,983
Taxes payable	4,003	2,768
Other accrued liabilities	12,400	11,353
Total accrued liabilities	$ 31,195	$ 30,133

Balance Sheet Components - Accu

Balance Sheet Components - Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Stockholders' Equity, Beginning of period	$ 402,388	$ 390,098	$ 348,997
Other comprehensive income (loss) before reclassifications	(6,649)	(1,369)
Amounts reclassified from other comprehensive income (loss), net of tax	(140)	0
Other comprehensive loss	(6,789)	(1,369)	(1,532)
Stockholders' Equity, End of period	431,607	402,388	390,098
Foreign currency translation adjustments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Stockholders' Equity, Beginning of period	(2,730)	(1,361)
Other comprehensive income (loss) before reclassifications	(8,034)	(1,369)
Amounts reclassified from other comprehensive income (loss), net of tax	0	0
Other comprehensive loss	(8,034)	(1,369)
Stockholders' Equity, End of period	(10,764)	(2,730)	(1,361)
Unrealized gain (loss) on interest rate swap hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Stockholders' Equity, Beginning of period	0	0
Other comprehensive income (loss) before reclassifications	1,385	0
Amounts reclassified from other comprehensive income (loss), net of tax	(140)	0
Other comprehensive loss	1,245	0
Stockholders' Equity, End of period	1,245	0	0
Accumulated Other Comprehensive Income
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Stockholders' Equity, Beginning of period	(2,730)	(1,361)	171
Other comprehensive loss	(6,789)	(1,369)	(1,532)
Stockholders' Equity, End of period	$ (9,519)	$ (2,730)	$ (1,361)

Net Investment in Sales-Type 49

Net Investment in Sales-Type Leases - Long Term Net Investment in Sales Type Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Net Investment in Sales-Type Leases
Collective allowance for credit losses	$ 300	$ 200
Net minimum lease payments to be received	33,591	22,255
Less: unearned interest income portion	(2,763)	(1,014)
Net investment in sales-type leases	30,828	21,241
Less: short-term portion	(10,243)	(6,757)
Long-term investment in sales-type leases, net	$ 20,585	$ 14,484
Minimum
Net Investment in Sales-Type Leases
Terms of sales-type leases (generally up to five years in length)	1 year
Maximum
Net Investment in Sales-Type Leases
Terms of sales-type leases (generally up to five years in length)	5 years

Net Investment in Sales-Type 50

Net Investment in Sales-Type Leases - Capital Leases, Future Minimum Payments Receivable (Details) $ in Thousands	Dec. 31, 2016USD ($)
Leases [Abstract]
2,017	$ 11,172
2,018	7,934
2,019	6,240
2,020	4,303
2,021	2,396
Thereafter	1,546
Total	$ 33,591

Goodwill and Intangible Asset51

Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Goodwill [Roll Forward]
Beginning balance		$ 147,906	$ 122,720
Additions		184,431	26,197
Adjustments		(4,613)	(1,011)
Ending balance	$ 147,906	327,724	147,906
Goodwill, purchase accounting adjustments		1,200
Mach4
Goodwill [Roll Forward]
Goodwill, purchase accounting adjustments	100
Automation and Analytics
Goodwill [Roll Forward]
Beginning balance		54,316	28,543
Additions		163,599	26,197
Adjustments		(2,833)	(424)
Ending balance	54,316	215,082	54,316
Medication Adherence
Goodwill [Roll Forward]
Beginning balance		93,590	94,177
Additions		20,832	0
Adjustments		(1,780)	(587)
Ending balance	$ 93,590	$ 112,642	$ 93,590

Goodwill and Intangible Asset52

Goodwill and Intangible Assets - Intangible Assets, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 245,128	$ 110,851
Accumulated amortization	(54,059)	(20,501)
Foreign currency exchange rate fluctuations	(786)	(685)
Net carrying amount	$ 190,283	89,665
Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	1 year
Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	30 years
Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 133,358	69,554
Accumulated amortization	(20,930)	(11,315)
Foreign currency exchange rate fluctuations	(596)	(719)
Net carrying amount	$ 111,832	$ 57,520
Customer relationships \| Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	1 year	5 years
Customer relationships \| Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	30 years	30 years
Acquired technology
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 73,599	$ 30,870
Accumulated amortization	(13,287)	(6,088)
Foreign currency exchange rate fluctuations	(159)	59
Net carrying amount	$ 60,153	$ 24,841
Acquired technology \| Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	3 years	3 years
Acquired technology \| Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	20 years	20 years
Backlog
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 20,550	$ 415
Accumulated amortization	(14,083)	(163)
Foreign currency exchange rate fluctuations	0	(11)
Net carrying amount	$ 6,467	$ 241
Useful Life (Years)		2 years
Backlog \| Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	1 year
Backlog \| Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	3 years
Trade name
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 8,667	$ 8,052
Accumulated amortization	(3,887)	(2,551)
Foreign currency exchange rate fluctuations	(31)	(14)
Net carrying amount	$ 4,749	$ 5,487
Trade name \| Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	1 year	1 year
Trade name \| Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	12 years	12 years
Patents
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 3,154	$ 1,960
Accumulated amortization	(1,264)	(384)
Foreign currency exchange rate fluctuations	0	0
Net carrying amount	$ 1,890	$ 1,576
Patents \| Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	2 years	2 years
Patents \| Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	20 years	20 years
Non-compete
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 1,900
Accumulated amortization	(608)
Foreign currency exchange rate fluctuations	0
Net carrying amount	$ 1,292
Useful Life (Years)	3 years
In-process research and development
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 3,900
Accumulated amortization	0
Foreign currency exchange rate fluctuations	0
Net carrying amount	$ 3,900

Goodwill and Intangible Asset53

Goodwill and Intangible Assets - Future Amortization Expense for Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 36,100	$ 6,900	$ 4,600
2,017	25,173
2,018	22,840
2,019	17,402
2,020	16,255
2,021	14,854
Thereafter (including IPR&D)	93,759
Total intangibles assets, net carrying amount	$ 190,283	$ 89,665

Debt and Credit Agreement - 201

Debt and Credit Agreement - 2016 Debt facilities narrative (Details) - Wells Fargo Bank, National Association - USD ($)	Dec. 02, 2016	Jan. 05, 2016	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2013	Sep. 25, 2013
Debt Instrument [Line Items]
Long-term debt, fair value			$ 256,500,000
Proceeds from debt			295,000,000
Debt issuance cost, net			6,359,000	$ 0
Debt issuance cost, gross			7,949,000
Secured Credit Facility \| Line of Credit
Debt Instrument [Line Items]
Revolving credit facility		$ 400,000,000
Secured Credit Facility \| Line of Credit \| Interest Rate Option One \| LIBOR \| Minimum
Debt Instrument [Line Items]
Amounts draw under the Credit Agreements bears interest rate		1.50%
Secured Credit Facility \| Line of Credit \| Interest Rate Option One \| LIBOR \| Maximum
Debt Instrument [Line Items]
Amounts draw under the Credit Agreements bears interest rate		2.25%
Secured Credit Facility \| Line of Credit \| Interest Rate Option Two \| LIBOR \| Minimum
Debt Instrument [Line Items]
Amounts draw under the Credit Agreements bears interest rate		0.50%
Secured Credit Facility \| Line of Credit \| Interest Rate Option Two \| LIBOR \| Maximum
Debt Instrument [Line Items]
Amounts draw under the Credit Agreements bears interest rate		1.25%
Secured Credit Facility \| Line of Credit \| Interest Rate Option Two \| Federal Funds
Debt Instrument [Line Items]
Amounts draw under the Credit Agreements bears interest rate		0.50%
Revolving Credit Facility
Debt Instrument [Line Items]
Proceeds from debt			95,000,000
Revolving Credit Facility \| Line of Credit
Debt Instrument [Line Items]
Revolving credit facility		$ 200,000,000				$ 75,000,000
Debt instrument, term		5 years
Proceeds from debt		$ 55,000,000
Revolving Credit Facility \| Line of Credit \| Minimum
Debt Instrument [Line Items]
Commitment fee percentage		0.20%
Revolving Credit Facility \| Line of Credit \| Maximum
Debt Instrument [Line Items]
Commitment fee percentage		0.35%
Term Loan Facility
Debt Instrument [Line Items]
Proceeds from debt			$ 200,000,000
Term Loan Facility \| Line of Credit
Debt Instrument [Line Items]
Revolving credit facility		$ 200,000,000
Debt instrument, term		5 years
Periodic payment, principal percent years one and two		5.00%
Periodic payment, principal percent years three and four		10.00%
Periodic payment, principal percent year five		15.00%
Proceeds from debt	$ 40,000,000	$ 200,000,000
Letter of Credit
Debt Instrument [Line Items]
Revolving credit facility		$ 10,000,000
Letter of Credit \| Line of Credit
Debt Instrument [Line Items]
Revolving credit facility					$ 10,000,000
Letter of Credit \| Line of Credit \| Minimum
Debt Instrument [Line Items]
Commitment fee percentage		1.50%
Letter of Credit \| Line of Credit \| Maximum
Debt Instrument [Line Items]
Commitment fee percentage		2.25%
Bridge Loan [Member]
Debt Instrument [Line Items]
Revolving credit facility		$ 10,000,000

Debt and Credit Agreement - Rol

Debt and Credit Agreement - Rollforward of 2016 new debt (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Amortization of debt financing fees	$ 1,590	$ 0	$ 0
Long term debt, current portion, net of deferred issuance cost	8,410	0
Long term debt, net of deferred issuance cost	245,731	0
Wells Fargo Bank, National Association
Debt Instrument [Line Items]
Long-term Line of Credit, Gross	260,500	0
Proceeds from debt	295,000
Repayment of debt and revolving credit facility	(34,500)
Debt issuance cost, net	(6,359)	0
Debt issuance cost, gross	(7,949)
Amortization of debt financing fees	1,590
Long-term Debt	254,141	0
Proceeds from Long-term Lines of Credit, Net of Financing Costs	287,051
Repayments of Lines of Credit, Net of Financing Costs	32,910
Long term debt, current portion, net of deferred issuance cost	8,410
Long term debt, net of deferred issuance cost	245,731
Term Loan Facility \| Wells Fargo Bank, National Association
Debt Instrument [Line Items]
Long-term Line of Credit, Gross	192,500	0
Proceeds from debt	200,000
Repayment of debt and revolving credit facility	(7,500)
Revolving Credit Facility \| Wells Fargo Bank, National Association
Debt Instrument [Line Items]
Long-term Line of Credit, Gross	68,000	$ 0
Proceeds from debt	95,000
Repayment of debt and revolving credit facility	$ (27,000)

Debt and Credit Agreement - 256

Debt and Credit Agreement - 2013 Credit Agreement (Details) - Wells Fargo Bank, National Association - USD ($)	Jan. 05, 2016	Sep. 30, 2013	Sep. 25, 2013
Letter of Credit
Debt Instrument [Line Items]
Revolving credit facility with a letter of credit sub limit	$ 10,000,000
Line of Credit \| Letter of Credit
Debt Instrument [Line Items]
Revolving credit facility with a letter of credit sub limit		$ 10,000,000
Increases in to aggregate commitments (does not exceed $25 million)		$ 25,000,000
Line of Credit \| Revolving Credit Facility
Debt Instrument [Line Items]
Revolving credit facility with a letter of credit sub limit	200,000,000		$ 75,000,000
Line of Credit \| Secured Credit Facility
Debt Instrument [Line Items]
Revolving credit facility with a letter of credit sub limit	$ 400,000,000

Deferred Revenue (Details)

Deferred Revenue (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred Revenue Disclosure [Abstract]
Deferred service revenue, cost of sales, current	$ 14,200	$ 15,700
Long-term deferred revenue	$ 17,051	$ 17,975

Commitments and Contingencies58

Commitments and Contingencies (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Rent expense	$ 9,800	$ 7,000	$ 6,800
2,017	11,300
2,018	10,994
2,019	10,995
2,020	7,358
2,021	6,719
Thereafter	10,326
Total minimum future lease payments	57,692
Purchase obligation due in the next twelve months	$ 42,900
Standard product warrant, duration following installation	30 days
Medication packaging system duration of limited warranties	6 months

Employee Benefits and Share-B59

Employee Benefits and Share-Based Compensation - Stock Purchase Plan (Details) - USD ($) shares in Thousands, $ in Thousands	May 19, 2009	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares added to reserved for future issuance (in shares)	2,600
Shares reserved for future issuance (in shares)		9,907
1997 Employee Stock Purchase Plan \| Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum percentage of earnings allowed for purchase of shares		15.00%
Maximum fair market value of shares		$ 25
Purchase price of common stock, percent		85.00%
Shares added to reserved for future issuance (in shares)	3,000
Shares reserved for future issuance (in shares)		2,831
Share of common stock purchased		400
Shares issued for the 1997 Employee Stock Purchase Plan		5,500
Unrecognized compensation cost		$ 3,500
Weighted average period of compensation cost recognized		14 months 30 days

Employee Benefits and Share-B60

Employee Benefits and Share-Based Compensation - Stock Award Plans (Details)

Mar. 07, 2016shares

Mar. 03, 2015shares

Mar. 20, 2014

Dec. 16, 2010shares

Oct. 01, 2010

May 19, 2009shares

Dec. 31, 2014Day

Dec. 31, 2013shares

Dec. 31, 2016moshares

Dec. 31, 2015shares

Dec. 31, 2014shares

Dec. 31, 2013shares

Dec. 31, 2012shares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Reduction to share available for issuance (in per share)

2.15

Increase to shares authorized (in shares)

2,600,000

Shares reserved for future issuance (in shares)

9,907,000

Performance Shares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Period used to calculate annual rates of return

1 year

Trading days | Day

Performance Shares | Vesting years subsequent the date of grant

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

3 years

Awards eligible for vesting (in shares)

60,000

Awards vested by period end (in shares)

30,000

2009 Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares authorized for issuance

2,600,000

Reduction to share available for issuance (in per share)

1.8

1.4

Increase to shares authorized (in shares)

3,200,000

2,500,000

Shares reserved for future issuance (in shares)

7,076,000

2009 Plan | Vesting one year from the vesting commencement date

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Percentage of award vesting

25.00%

2009 Plan | Employee Stock Option

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

4 years

Shares reserved for future issuance (in shares)

3,214,000

2009 Plan | Employee Stock Option | Vesting one year from the vesting commencement date

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

1 year

2009 Plan | Employee Stock Option | Vesting in equal monthly installments

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Monthly vesting installments | mo

2009 Plan | Restricted Stock Units (RSUs)

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

4 years

Shares reserved for future issuance (in shares)

719,000

Shares granted (in shares)

289,000

Vested (in shares)

179,000

2009 Plan | Performance Shares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares granted (in shares)

123,000

Vested (in shares)

90,000

2013 Performance Based Restricted Stock Units | Performance Shares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Percentage of shares eligible for time-based vesting

100.00%

2013 Performance Based Restricted Stock Units | Performance Shares | Vested immediately

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Percentage of award vesting

25.00%

2014 Performance Based Restricted Stock Units | Performance Shares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Awards eligible for vesting (in shares)

132,500

Awards vested by period end (in shares)

93,000

Percentile rank of stockholder return

66.00%

74.40%

Officer | Performance Shares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares granted (in shares)

137,500

122,740

60,000

132,500

125,000

Awards eligible for vesting (in shares)

62,500

Employee Benefits and Share-B61

Employee Benefits and Share-Based Compensation - Valuation of Share Based Awards, Table (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.50%	1.70%	1.60%
Dividend yield	0.00%	0.00%	0.00%
Expected volatility	30.60%	32.00%	34.90%
Expected life	4 years 10 months 24 days	5 years	4 years 9 months 18 days
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility, minimum	25.80%	25.70%	29.50%
Expected volatility, maximum	34.80%	37.50%	42.10%
ESPP Risk-free interest rate, minimum	0.34%	0.03%	0.03%
ESPP Risk-free interest rate, maximum	0.79%	0.79%	0.53%
Employee Stock \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	6 months	6 months	6 months
Employee Stock \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	2 years	2 years	2 years
1997 Employee Stock Purchase Plan \| Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%	0.00%

Employee Benefits and Share-B62

Employee Benefits and Share-Based Compensation - Shared-Based Compensation Expense (Details) - 2009 Plan - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	$ 19,500	$ 14,921	$ 12,785
Income tax benefit	5,400	5,000	4,500
Cost of product and service revenues
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	2,596	2,111	1,456
Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	3,128	2,060	1,655
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	$ 13,776	$ 10,750	$ 9,674

Employee Benefits and Share-B63

Employee Benefits and Share-Based Compensation - Stock Option Activity (Details) - 2009 Plan - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Number of Shares
Outstanding at December 31, 2015	2,688
Granted (Awarded)	1,055
Exercised (Released)	(406)
Expired	(8)
Forfeited	(115)
Outstanding at December 31, 2016	3,214	2,688
Exercisable at December 31, 2016	1,487
Vested and expected to vest at December 31, 2016 and thereafter	3,007
Weighted-Average Exercise Price
Outstanding at December 31, 2015	$ 22.89
Granted (Awarded)	32.11
Exercised (Released)	19.58
Expired	30.43
Forfeited	30.19
Outstanding at December 31, 2016	26.06	$ 22.89
Exercisable at December 31, 2016	20.23
Vested and expected to vest at December 31, 2016 and thereafter	$ 25.66
Outstanding at December 31 (in years)	7 years 3 months	6 years 11 months
Exercisable at December 31, 2014 (in years)	5 years 5 months
Vested and expected to vest at December 31, 2014 (in years)	7 years 2 months
Outstanding at December 31, 2016	$ 26,331
Exercisable at December 31, 2016	20,459
Vested and expected to vest at December 31, 2016 and thereafter	$ 25,778
Employee Stock Option
Weighted-Average Exercise Price
Weighted-average fair value (in usd per share)	$ 9.33	$ 9.67	$ 9.12
Intrinsic value of options exercised	$ 5,600	$ 11,300	$ 14,100
Unrecognized compensation cost of unvested stock options	$ 13,300	$ 11,200
Weighted average period of compensation cost recognized	3 years	2 years 11 months

Employee Benefits and Share-B64

Employee Benefits and Share-Based Compensation - Restricted Stock Activity (Details) - 2009 Plan - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Restricted Stock Units (RSUs)
Number of Shares
Outstanding and unvested December 31	417
Granted (Awarded)	289
Vested (Released)	(179)
Forfeited	(22)
Outstanding and unvested at December 31	505	417
Weighted-Average Grant Date Fair Value
Outstanding and unvested December 31	$ 28.49
Granted (Awarded)	32.58	$ 31.44	$ 28.88
Vested (Released)	26.83
Forfeited	28.37
Outstanding and unvested at December 31	$ 31.42	$ 28.49
Weighted-Average Remaining Years	1 year 7 months 5 days	1 year 7 months
Aggregate Intrinsic Value
Non-vested at December 31, 2016	$ 17,135
Fair value of restricted stock units	4,800	$ 4,700	$ 3,200
Unrecognized compensation cost	$ 12,800	$ 11,200
Weighted average period of compensation cost recognized	2 years 10 months 17 days	2 years 10 months 15 days
Restricted Stock
Number of Shares
Outstanding and unvested December 31	31
Granted (Awarded)	34
Vested (Released)	(35)
Outstanding and unvested at December 31	30	31
Weighted-Average Grant Date Fair Value
Outstanding and unvested December 31	$ 35.97
Granted (Awarded)	31.59	$ 36.05	$ 26.42
Vested (Released)	35.45
Forfeited	0
Outstanding and unvested at December 31	$ 31.57	$ 35.97
Aggregate Intrinsic Value
Fair value of restricted stock units	$ 1,200	$ 1,100	$ 1,000
Unrecognized compensation cost	$ 400
Weighted average period of compensation cost recognized	4 months 15 days	4 months 15 days

Employee Benefits and Share-B65

Employee Benefits and Share-Based Compensation - Performance Based Restricted Stock Units Awards (Details) - 2009 Plan - Performance Shares - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Number of Shares
Outstanding and unvested December 31	151
Granted (Awarded)	123
Vested (Released)	(90)
Forfeited	0
Outstanding and unvested at December 31	184	151
Weighted-Average Grant Date Fair Value
Outstanding and unvested December 31	$ 23.33
Granted (Awarded)	24.66	$ 29.56	$ 20.94
Vested (Released)	21.95
Forfeited	0
Outstanding and unvested at December 31	$ 24.89	$ 23.33
Weighted average period of compensation cost recognized	1 year 2 months 12 days
Unrecognized compensation cost	$ 1.6	$ 1.5
Vested in period, fair value	$ 2	$ 1.9	$ 1.5

Employee Benefits and Share-B66

Employee Benefits and Share-Based Compensation - Summary of Shares Reserved for Future Issuance Under Equity Incentive Plans (Details) shares in Thousands	Dec. 31, 2016shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for future issuance	9,907
Nineteen Ninety Seven Employee Stock Purchase Plan [Member] \| ESPP shares available for future issuance
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for future issuance	2,831
Two Thousand Nine Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for future issuance	7,076
Two Thousand Nine Plan \| Share options outstanding
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for future issuance	3,214
Two Thousand Nine Plan \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for future issuance	719
Two Thousand Nine Plan \| future grants and awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for future issuance	3,143

Employee Benefits and Share-B67

Employee Benefits and Share-Based Compensation - 401(k) Plan (Details) - Other Postretirement Benefit Plan - Omnicell Plan - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Defined Contribution Plan Disclosure [Line Items]
Employer matching contribution, percent of employee contribution	50.00%
Maximum amount of employer contribution	$ 2,000
401(k) contributions	$ 1,900,000	$ 1,800,000	$ 1,300,000

Stock Repurchases (Details)

Stock Repurchases (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Aug. 02, 2016
Equity, Class of Treasury Stock [Line Items]
Total number of shares repurchased	0	1,424,000	884,000
Dollar amount of shares repurchased		$ 50,021	$ 24,091
Average price paid per share		$ 35.13	$ 27.24
August 2012 Stock Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Stock repurchases program, authorized amount				$ 50,000
2016 and 2014 Share Repurchase Programs [Member]
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, remaining authorized repurchase amount	$ 54,900

Segment and Geographical Info69

Segment and Geographical Information - Financial Performance of Reporting Segments (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)segment	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Segment Reporting [Abstract]
Number of segments \| segment	2
Number of reportable segments \| segment	2
Segment Reporting Information [Line Items]
Revenues	$ 692,623	$ 484,559	$ 440,900
Cost of revenues	378,823	236,629	207,040
Gross profit	313,800	247,930	233,860
Operating expenses	307,319	199,298	184,277
Income from operations	6,481	48,632	49,583
Operating Segments
Segment Reporting Information [Line Items]
Revenues	692,623	484,559	440,900
Cost of revenues	378,823	236,629	207,040
Gross profit	313,800	247,930	233,860
Operating expenses	223,354	138,342	126,515
Income from operations	90,446	109,588	107,345
Operating Segments \| Automation and Analytics
Segment Reporting Information [Line Items]
Revenues	593,626	390,321	354,095
Cost of revenues	310,967	171,943	151,327
Gross profit	282,659	218,378	202,768
Operating expenses	198,511	114,084	105,929
Income from operations	84,148	104,294	96,839
Operating Segments \| Medication Adherence
Segment Reporting Information [Line Items]
Revenues	98,997	94,238	86,805
Cost of revenues	67,856	64,686	55,713
Gross profit	31,141	29,552	31,092
Operating expenses	24,843	24,258	20,586
Income from operations	6,298	5,294	10,506
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Operating expenses	$ 83,965	$ 60,956	$ 57,762

Segment and Geographical Info70

Segment and Geographical Information - Additional Details by Geographical Location (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]
Total property and equipment, net	$ 42,011	$ 32,309	$ 36,178
Total revenues	692,623	484,559	440,900
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Total property and equipment, net	36,497	29,506	35,335
Total revenues	591,566	403,375	394,234
Non-US
Revenues from External Customers and Long-Lived Assets [Line Items]
Total property and equipment, net	5,514	2,803	843
Total revenues	$ 101,057	$ 81,184	$ 46,666

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Domestic	$ 1,471	$ 51,089	$ 48,327
Foreign	(3,419)	(4,845)	177
Income (loss) before provision for income taxes	$ (1,948)	$ 46,244	$ 48,504

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current:
Federal	$ 6,724	$ 13,840	$ 14,063
State	1,323	2,475	2,274
Foreign	46	203	192
Total current income taxes	8,093	16,518	16,529
Deferred:
Federal	(3,378)	846	1,603
State	(1,802)	(379)	84
Foreign	(5,464)	(1,501)	(230)
Total deferred income taxes	(10,644)	(1,034)	1,457
Total provision for (benefit from) income taxes	$ (2,551)	$ 15,484	$ 17,986

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
U.S. federal tax provision at statutory rate	$ (682)	$ 16,181	$ 16,998
State taxes	(311)	1,365	1,533
Non-deductible expenses	1,212	551	809
Acquisition costs	845	239	229
Share-based compensation expense	1,941	748	461
Research tax credits	(2,075)	(1,324)	(818)
Domestic production deduction	(890)	(1,133)	(1,127)
Gain on investment	0	(1,205)	0
Tax audit settlement	(2,499)	0	0
Other	(92)	62	(99)
Total provision for (benefit from) income taxes	$ (2,551)	$ 15,484	$ 17,986

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets (liabilities):
Deferred revenue	$ 5,857,000	$ 14,020,000
Stock compensation	6,451,000	6,034,000
Inventory related items	2,915,000	2,541,000
Tax credit carry forwards	4,871,000	2,579,000
Reserves and accruals	929,000	0
Loss carry forwards	8,077,000	667,000
Other, net	847,000	697,000
Total net deferred tax assets	29,947,000	26,538,000
Intangibles	(57,427,000)	(28,213,000)
Depreciation and amortization	(20,071,000)	(17,185,000)
Reserves and accruals	0	(601,000)
Other, net	0	0
Total deferred tax liabilities	(77,498,000)	(45,999,000)
Net deferred tax liabilities	(47,551,000)	$ (19,461,000)
Valuation allowance	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) $ in Millions	Dec. 31, 2016USD ($)
Tax Credit Carryforward [Line Items]
Unrecognized tax benefits that would impact tax expense	$ 7.6
Tax deferred expense, compensation and benefits	3
Undistributed foreign earnings	2.5
Income tax expense, if undistributed foreign earnings are distributed	1
Research Tax Credit Carryforward \| Internal Revenue Service (IRS)
Tax Credit Carryforward [Line Items]
Tax credit carryforward amount	1.7
Research Tax Credit Carryforward \| State and Local Jurisdiction
Tax Credit Carryforward [Line Items]
Tax credit carryforward amount	$ 7.2

Income Taxes - Schedule of Unre

Income Taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2016
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning of the Period Balance	$ 9,150	$ 8,485	$ 7,974
Increases related to tax positions taken during a prior period	244	37	63
Decreases related to tax positions taken during the prior period	(1,980)	(895)	(89)
Increases related to tax positions taken during the current period	6,724	1,807	801
Decreases related to settlements	(2,178)	0	0
Decreases related to expiration of statute of limitations	(344)	(284)	(264)
End of the Period Balance	$ 9,150	$ 8,485	$ 7,974	$ 11,616

2016 Restructuring Expenses (De

2016 Restructuring Expenses (Details) $ in Millions	3 Months Ended	12 Months Ended
2016 Restructuring Expenses (Details) $ in Millions	Jun. 30, 2016Employee	Dec. 31, 2016USD ($)
Restructuring and Related Activities [Abstract]
Number of positions eliminated \| Employee	36
Restructuring expense		$ 1.7
Restructuring payments		$ 1.7

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event $ in Millions	Feb. 15, 2017USD ($)Employee
Subsequent Event [Line Items]
Expected number of positions to be eliminated \| Employee	100
Expected cost \| $	$ 8

Schedule II Valuation and Qua79

Schedule II Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	$ 1,409	$ 1,368	$ 657
Charged to Cost and Expenses	812	354	941
Credited to Other Accounts	77	134	(65)
Amount Written Off	(369)	(447)	(165)
Balance at End of Period	5,050	1,409	1,368
Valuation Allowances and Reserves, Reserves of Businesses Acquired	3,121	0	0
Accounts Receivable
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	1,240	1,206	490
Charged to Cost and Expenses	727	453	941
Credited to Other Accounts	77	28	(60)
Amount Written Off	(369)	(447)	(165)
Balance at End of Period	4,796	1,240	1,206
Valuation Allowances and Reserves, Reserves of Businesses Acquired	3,121	0	0
Investment in sales-type leases
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	169	162	167
Charged to Cost and Expenses	85	(99)	0
Credited to Other Accounts	0	106	(5)
Amount Written Off	0	0	0
Balance at End of Period	254	169	162
Valuation Allowances and Reserves, Reserves of Businesses Acquired	$ 0	$ 0	$ 0